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ABSTRACT 
AIM:  
To study coagulation profile changes in pregnancy induced 
hypertension. Methods and Materials: Control group consists of 60 
normotensive pregnant women compared with 30 cases of non-severe 
PIH and 30 cases of severe PIH. Coagulation parameters BT, CT, Platelet 
Count, PT and APTT were done for all cases. Observations: Patients with 
severe PIH patients showed low Platelet Count, prolonged BT, PT and 
APTT compared to normotensive pregnant women and non-severe PIH. 
No changes observed in CT. Summary and Conclusion: The changes in 
Coagulation Profile in severe PIH is helpful in assessing the Coagulation 
abnormalities at earlier stage. Changes observed in the coagulation 
parameters as the severity of PIH increases. 
KEYWORDS: 
Pregnancy Induced Hypertension, Bleeding Time, Clotting Time, 
Platelet Count, Prothrombin Time, Activated Partial Thromboplastin 
Time. 
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INTRODUCTION 
 
Pregnancy induced hypertension is an elevated blood pressure that 
appears first time after five months of pregnancy. It is one of the most 
common cause of increased mortality and morbidity both in the mother 
and in the foetus.  
Preeclampsia is a combination of elevated blood pressure, 
proteinuria and edema. Eclampsia is the presence of convulsions along 
with above three features of preeclampsia. 
Normal pregnancy is a hypercoagulable state due to elevation of 
the most of the coagulation factors and reduced anticoagulant activity. In 
pregnancy induced hypertension, there is an accentuation of 
hypercoagulable state as a result of injury to the endothelium. 
Coagulation profile studied in pregnancy induced hypertension are 
platelet counts, bleeding time, clotting time, prothrombin time and 
activated partial thromboplastin time. These parameters are helpful in 
assessing the severity of coagulation abnormalities in pregnancy induced 
hypertension at earlier stage, prior to the occurrence of complications like 
HELLP Syndrome, disseminated intravascular coagulation and 
cerebrovascular complications. 
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Aim of the study is to find out the changes that occur in the 
coagulation parameters in pregnancy induced hypertension.Then it is 
compared with normotensive pregnant women. This study may help in 
reducing the mortality and morbidity that are caused by the coagulation 
abnormalities of the pregnancy induced hypertension. 
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AIM OF THE STUDY 
 
 Aim of the study is to find out the changes that occur in the 
coagulation parameters in pregnancy induced hypertension as compared 
to that in normal pregnancy.  
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OBJECTIVES 
 
1. To study the changes in platelet count, bleeding time, clotting time, 
prothrombin time and activated partial thromboplastin time in 
pregnancy induced hypertension. 
2. To study the above parameters in normal pregnant women. 
3. To compare the above parameters between normotensive pregnant 
women and women with pregnancy induced hypertension.  
4. To correlate the above parameters with severity of pregnancy 
induced hypertension. 
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REVIEW OF LITERATURE 
 
COAGULATION PROFILE STUDY IN PREGNANCY INDUCED 
HYPERTENSION 
Hypertensive disorders complicate 5 to 10% of all pregnancies and 
it is one of the major causes of maternal and foetal mortality and 
morbidity. As per WHO (Khan and colleagues, 2006) Hypertension and 
its complications contribute to 16% of maternal deaths in developed 
countries. Erg and colleagues study in United States (2003) reported that 
16% of maternal deaths are related to pregnancy related hypertension. 
TERMINOLOGY AND CLASSIFICATION 
 Working Group NHBPEP – National High Blood Pressure 
Education Programme (2000) Classification of Hypertensive Disorders 
complicating Pregnancy.[1] 
1. Gestational Hypertension or Pregnancy Induced 
Hypertension.[2],[3],[4] 
2. Preeclampsia and eclampsia Syndrome. 
3. Preeclampsia Syndrome superimposed on chronic hypertension. 
4. Chronic hypertension.[5],[6] 
PREGNANCY INDUCED HYPERTENSION 
Defined as significant raise in Blood Pressure after 20 weeks of 
pregnancy in a woman previously recorded normal blood pressure to 
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above 140 mm Hg systolic and 90 mm Hg diastolic and it is called as 
severe if the systolic blood pressure is above 160 mm Hg and the 
diastolic blood pressure is more than 110 mmHg.  Severity is determined 
by the presence or absence of certain factors. Presence of symptoms like 
Headache, Visual Disturbances, Upper abdominal Pain, Oliguria, 
Convulsion, Low platelet Count, Elevated serum enzymes and creatinine 
indicate severe pregnancy induced Hypertension. In the absence of 
abovementioned features it is called as non-severe. 
PATHOPHYSIOLOGY OF PREGNANCY INDUCED 
HYPERTENSION 
In 1939 Ernest introduced the concept that pathophysiology of 
pregnancy induced hypertension is impaired perfusion of the placenta. 
According to Oxford Group in 1991 and supported by Roberts there are 
two stages in the development of pregnancy induced hypertension. Stage 
one is reduced placental perfusion and the stage two is maternal 
endothelial cell activation.[7],[8] 
              In normal pregnancy cytotrophoblastic cells invade the decidua 
and myometrium. These cells replace the endothelium and media of the 
spiral arteries and as a result low resistance large diameter arterioles are 
formed. They become resistant to vasopressor agents and the perfusion of 
the placenta is increased.[9] 
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In PIH the incomplete endovascular trophoblastic invasion occurs 
only in the decidual vessels but not in the myometrial vessels and these 
vascular changeslead toendothelial damage, proliferation of myointimal 
cells, medial necrosis and lipid accumulation in myointimal cells and 
macrophages. This was referred as atherosis by Hertig 
(1945).Superimposed thrombosis leads to hypoperfusion, hypoxia and 
release of placental debris. 
PATHOPHYSIOLOGICAL CHANGES IN PREGNANCY 
INDUCED HYPERTENSION 
              Hyperdynamic circulation is caused by increase in maternal 
cardiac output .The systemic vascular resistance is altered compared to 
normotensive pregnant women and there is hyperdynamic left ventricular 
function.[10] 
             Intravascular volume during normal pregnancy is increased 
whereas in PIH there is minimal increase or no increase in intravascular 
volume. This is because of generalised constriction of the venules.[11] 
 The limited blood volume mainly affects the plasma volume so 
that there is development of hemoconcentration. 
  There is loss of resistance to the angiotensin II and 
catacholamines.The most important complication affecting the 
coagulation system in PIH is HELLP syndrome which consists of 
Haemolytic anaemia, Elevated Liver enzymes and Low Platelet count. 
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MORPHOLOGICAL CHANGES IN PREGNANCY INDUCED 
HYPERTENSION 
KIDNEY:     
 The characteristic lesion is glomerular endotheliosis which is well 
demonstrated by electron microscopy. There is deposition of osmophilic 
material between the basal membrane and the endothelial cells which 
leads to the narrowing of the capillary lumen and there is increase in the 
cytoplasm of endothelial cells and mesangial cells. There is no change in 
the epithelial cells or foot processes, no proliferation ofmesangial cells, 
and no alteration in the architecture of the renal medulla. The nature of 
the osmophilic deposits on immunofluorescent technique shows material 
that reacts with antibodies against fibrinogen and fibrin.[12],[13],[14],[15] 
LIVER:  
 The same kind of material present in the kidney is also found in 
the liver. There are many areas of subcapsular haemorrhage. In the 
periphery of the lobules there is presence of fibrin thrombi and 
surrounding this thrombi are areas of haemorrhage and necrosis called 
asperiportal haemorrhagicnecrosis.[16],[17] 
FACTORS RELEASED FROM THE PLACENTA IN 
PREGNANCY INDUCED HYPERTENSION 
1. Oxidative stress[18],[19],[20] 
2. Cytokines includeTumour necrosis factor2 and Interlukein -6 
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3. Insulin like growth factors 
4. Heparin binding endothelial growth factor-like growth factor. 
5. Endothelin  
6. Arachidonic acid metabolites. 
7. Angiotensin type II – type1 receptor autoantibody and angiogenic 
factors.[21] 
 Study conducted by Reem Mustafa[22] et al in the year 2012 
reveals that the imbalance of proangiogenic and antiangiogenic factors is 
an important factor in the pathogenesis of pregnancy induced 
hypertension. There is increased expression of soluble fms –like tyrosine 
kinase.It is an antiangiogenic factor.It antagonizes vascular endothelial 
growth factor and placental growth factor. Soluble endoglin is a placenta 
derived coreceptor for transforming growth factor beta. It antagonises the 
effect of transforming growth factor beta which is an angiogengic factor. 
[23],[24],[25],[26],[27] 
ENDOTHELIAL CELL ACTIVATION 
 As a result of damaged endothelial cells the amount of nitric 
oxide and prostacyclin production by the endothelium becomes 
less.[28],[29],[30],[31],[32],[33],[34],[35],[36] 
 For the pathogenesis of pregnancy induced hypertension, the 
activation and damage of endothelial cells is an important mechanism.It 
was a study conducted by J.Heimrath[37] et al in the year 2007. 
 10 
ROLE OF ANGIOGENIC AND ANTIANGIOGENIC PROTEINS 
 By the time of 21 days of pregnancy placental vasculogenesis is 
established.Two antiangiogenic peptides involved in PIH are [38],[39] 
1. Soluble Fms- like tyrosine kinase 1  
 Increased levelof this cause reduction of placental growth factor 
and vascular endothelial growth factor leading to dysfunction of 
endothelium.[40],[41] 
2. Soluble endoglin 
 It inhibits Transforming Growth factor-beta isotopes. 
COAGULATION CHANGES IN NORMAL PREGNANCY 
1. Fibrinogen  
 Fibrinogenlevelin nonpregnant women ranges from 200 to 400 
mg/dL. In pregnant women the level increases and can reach 
upto600mg/dL in the third trimester. [42],[43],[44] 
2. Clotting factors VII, VIII, IX and X levels are increased and there is no 
change in factors II and XI. 
3. Activated Partial Thromboplastin Time is shortened. 
4. Protein C is unchanged and there is acquired activated protein C 
resistance. 
5. Protein S levels are reduced. 
6. Markers of thrombin production are elevated in pregnancy. 
7. D-Dimer levels are high compared to non-pregnant level. 
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8. Fibrinolysis  
 It is suppressed and there is elevation of plasminogen activator 
inhibitor. Placenta produces plasminogen Activator inhibitor-1 and it is 
the main source of plasminogen activator inhibitor-2 which plays a main 
role in reduction in tissue plasminogen activator activity. Compared to 
non-pregnant level at normal term pregnancy the level of plasminogen 
activator inhibitor-2 is 25 times high.[45],[46],[47] 
9. Platelets 
 As a result of increased consumption there is a moderate decrease 
in the platelet concentration as pregnancy advances. Regarding lifespan 
andfunction there is no change. Mean platelet size increases throughout 
the gestation. Due to accelerated production of platelets from the bone 
marrow platelet distribution width increases. Gestational 
thrombocytopenia is not a pathological condition and it the most common 
cause of thrombocytopenia during pregnancy. In pregnancy 5 to 8 per 
cent of women show low platelet count .There is no risk of bleeding even 
though there is platelet count as low as 1,00,000 per cubicmillimeter. 
Enhanced platelet activity compensates the low platelet count. Low 
platelet count may be due to the effect of dilutional thrombocytopenia. 
Greater numbers of younger platelets are present in the circulation. In the 
smear they appear large. A high level of thromboxaneA2 in pregnancy 
causes platelet aggregation.[48],[49],[50],[51] 
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 Hence pregnancy is a hypercoagulable state because of the 
changes in the coagulation and fibrinolysis. Thromboplastic substances 
released at the time of delivery from the placenta stimulate clot 
formation. Physiological adaptations occurring during pregnancy are to 
help the mother from untoward bleeding complications during 
labour.[52],[53],[54],[55],[56],[57],[58],[59],[60],[61],[62],[63],[64] 
COAGULATON CHANGES IN PREGNANCY INDUCED 
HYPERTENSION 
 Reduction in the formation of vasodilator and antiplatelet agents 
such as prostacyclin and nitric oxide in association with increased levels 
of endothelin the endothelium becomes antithrombotic to 
prothrombotic.Downregulation of fibrinolytic system occurs.  
Thrombocytopenia is due to  
1. Reduction of platelet lifespan 
2. Increased platelet consumption 
3. Decreased prostacyclin synthesis 
4. Immunological mechanisms. 
 Rahim[65] et al study in  the year 2010 revealed that low platelet 
count was present in  disseminated intravascular coagulation. 
FahirElsirmohammed[66] et al study in the year 2013 revealed that 
the mean platelet volume and platelet distribution width were increased 
and the count of the platelet is reduced. Their study also proved that for 
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the assessment of pregnancy induced hypertension the platelet estimation 
is a rapid and simple cost effective method to diagnose the 
haematological changes. 
 Fitz Gerald [67] et al study in 1966   said that the estimation of 
prothrombin time, activated partial thromboplastin time and fibrinogen 
level are important in patients with pregnancy induced hypertension. In 
their study they found out in the presence of normal platelet count, there 
were minor changes in the prothrombin time, activated partial 
thromboplastin time and fibrinogen level. 
 S.Kawaguchi[68] et al study in year 2013 showed that increased D-
Dimer levels during third trimester of pregnancy in patients with 
pregnancy induced hypertension.  
 Srivatsava[69] et al study in  the year1995 revealed thatseverity of 
pregnancy induced hypertension can be assessed by reduction in 
antithrombinIIIlevel. 
NORMAL HAEMOSTASIS 
 Depends upon three important factors such as 
1. Platelets 
2. Coagulation system 
3. Vascular endothelium 
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PLATELETS 
 In 1841 Addison described as extremely minute granules. 
Recognised in 1882 by Bizzozero as cell structure having adhesive 
properties termed platelets and does not come under white blood cells or 
red blood cells. Osler and schaeter, in 1970 described the role in 
haemostasis and thrombosis. The bone marrow cell was called as 
megakaryocyte by Howell in 1890.James Homer Wright identified that 
platelets are produced from bone marrow precursor cell megakaryocyte in 
1906. 
            They are discoid shaped cells and products of fragments of 
megakaryocyte cytoplasm.Interaction of platelets with coagulation 
system and vascular endothelium plays a major role in normal 
haemostasis. 
DEVELOPMENT 
 During foetal life platelets are produced from the yolksac and the 
production of platelets is shifted later to the liver and then to the 
bonemarrow. Hematopoietic stem cells are found in the intraembryonic 
aorta and gonad mesonephros region.During the third month of foetal life 
stem cells migrate to the liver. By birth bonemarrow becomes the 
hematopoietic organ.[70] 
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STAGES OF DEVELOPMENT 
Pleuripotent hematopoietic stem cell 
↓ 
Common myeloid progenitor 
↓ 
Colony forming unit erythroid megakaryocyte 
↓ 
Burst forming unit megakaryocyte 
↓ 
Megakaryoblast(stage-1) 
↓ 
Megakaryocyte (stage II/III/IV) 
↓ 
Platelet 
 Endomitosis is an important feature in megakaryocyte 
development in which DNA replication occurs without cell division. 
Through repeated cycles of DNA replication megakaryocytes become 
polyploid. They enter into anaphaseA and do not enter into anaphaseB. 
There is reduction in mitosis promoting factor or reduced expression of 
cyclin B and overexpression of cyclinD in the phase of maturing 
megakaryocytes. Absence of chromosomal passenger proteins 
AuroraB/Aim-1 and Survivin.[71] 
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 Cytoplasmic maturation begins during endomitosis and formation 
of specific protein organelles and membrane systems. The internal 
membrane system in the mature megakaryocyte is referred as 
demarcation membrane system.There is formation of platelet territories 
within the cytoplasm. Fragmentation of cytoplasm produces platelets 
along demarcation membrane fracture lines between platelet territories. 
Young platelets contain ribonucleic acid and are called reticulate 
platelets. Large and beaded platelets are produced under stress are called 
as stress platelets.The time taken for the production of 1000 to 5000 
platelets from one megakaryocyte is about ten days. 
THROMBOPOIETIN   
 It is a glycoprotein hormone produced mainly from the 
parenchymal cells and sinusoidal endothelial cells of liver and proximal 
convoluted tubule cells of the kidney. It is also produced in minimal 
amount by skeletal muscle and stromal cells of the bone marrow. It binds 
to the mpl receptor present in the megakaryocyte and platelet. 
Functions of thrombopoietin are 
1. Proliferation and maturation of megakaryoblast 
2. Regulate the development of megakaryocyte in all stages from the 
stem cell. 
3. Increase in size and number of megakaryocytes so that the number 
of platelet production is also increased. 
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 Other factors involved in thrombopoiesis are Cytokine stem cell 
factor,Granulocyte macrophage colony stimulating factor and 
Interleukins-3,6and11. 
 Once released from the bone marrow majority will be present in 
the circulation and 20% present in the spleen.There is no reserve in the 
bone marrow. The normal platelet count is 250x109(Range150-400x109). 
Each platelet makes 14,000 drips through the blood stream in its life span 
of 7 to 10 days. In the circulation they exist in two forms,one is resting 
form and the other one is active form. Mean diameter of platelet is 1-2 
µm and the mean cell volume is 5.8fl.[71],[72],[73] 
STRUCTURE OF PLATELETS 
By ultrastructure three zones are studied 
ZONE ONE – PERIPHERAL ZONE-It contains exterior coat,cell 
membrane and open canalicular system. 
ZONE TWO – CYTOSKELETAN OR SOL-GEL ZONE - This consists 
of   microfilaments, circumferential microtubules and dense tubular 
system. 
ZONE THREE- ORGANELLE ZONE- This contains alpha granules, 
dense granules, mitochondria and lysosomes.  
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Ultra structure of platelets 
 
EXTERIOR COAT 
 It contains glycoproteins, glycolipids,mucopolysaccharides and 
absorbed plasma proteins.Thickness of this coat is 15 to 20 nm. It has 
close contact with cellular and fluid component of the blood.It covers the 
plasma membrane and also the surface connected canalicular system. The 
interior contents pass through this coat into blood by endocytosis. 
THE PLASMA MEMBRANE  
 Trilaminar membrane composed of proteins, lipids and 
carbohydrates. The content of bilayered lipid layer is mainly composed of 
phospholipids and the distribution is asymmetrical. Prostaglandins are 
produced from the phospholipids.It also controls the transport of sodium 
and calcium ions by the presence of pumps like sodium- and calcium-
adenosine triphosphates.The presence of negatively charged 
phosphatidylserine in the inner leaflet controls the coagulation. 
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SURFACE CONNECTED SYSTEM 
 It is the modification of the plasma membrane over the surface. 
The functions of this system are storage for membrane glycoproteins such 
as GPIb-IX-V and GPIIb-IIIa, pathway for release of secretory granules 
when the platelets are activated, act as a barrier between blood and 
platelet and helpful for adhesion of platelets by spreading the 
membrane.[74],[75],[76],[77] 
CYTOSKELETON(SOL-GEL ZONE) 
DENSE TUBULAR SYSTEM 
             It is one of the sites for prostaglandin production. It is nothing but 
smooth endoplasmic reticulum of the megakaryocyte and in electron 
microscopy it appears as an amorphous electron dense material. It 
contains peroxidase, glucose-6 phosphatase, adenylatecyclase and 
calcium and magnesium activated adenine triphosphatase. [78] 
MICRO FILAMENTS 
 They are binding proteins in which actin constitutes 20-30% of 
the total platelet protein and myosin constitutes 2-5% of the total platelet 
protein. They are responsible for platelet retraction/contraction and 
platelet shape. Under stimulation of platelets the actin monomers 
polymerize and fill the developing filopodia. Phosphorylation of myosin 
results in binding of myosin with actin and gives tension for filopodia.[79] 
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MICROTUBULES: 
           Disassembly and reassembly occur under platelet activation. It 
consists of two subunits which are not identical. Micro tubule coil lies 
just adjacent to the plasma membrane. It plays an important role in 
platelet formation from megakaryocytes and in maintaining the discoid 
shape of the platelet. 
ORGANALLE ZONE: 
 Responsible for platelet storage and platelet release functions. 
ALPHA GRANULES: 
 They are the predominate granules present in the platelet. Each 
platelet contains about 50-80 alpha granules. The size is 200-300nm.It 
contains Thrombospondin, von Willebrand factor, Multimerin, 
Fibrinogen, Fibronectin, Vitronectin and P-selectin which are responsible 
for platelet adhesion. P-selectin is transferred to the plasma membrane 
under the effect of platelet activation. The growth modulators present are 
platelet derived growth factor and transforming growth factor-β. The 
platelet specific proteins present are platelet factor 4 and β-
thromboglobulin.  
 The two important coagulation proteins are fibrinogen and factor 
5 and other coagulation factors are factor XI,protein S and plasminogen 
activator inhibitor-1. The granules are spherical in shape with outer 
membrane. The membrane consists of large electron dense region and 
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low electron dense zone. The platelet specific proteins are present in 
dense region. Adhesive proteins are present in low electron dense zone. 
Megekrayocyte produces β-thromboglobulin, platelet factor 4, 
thrombospondin and von Willebrand factor. 
DENSE GRANULES 
 They are few in number and opaque, normally 3-8 per platelet. 
The size of the granule is 20-30nm.The content of the dense granules are  
high concentrations of serotonin, calcium, adenosine  diphosphate and 
adenosine triphosphate .Granule membrane contains P-selectin and 
granulophysin.From the plasma high concentrations of serotonin is 
transferred to the granules through the plasma membrane. Serotonin is 
responsible for platelet coagulant activity, liver regeneration and 
vasospasm. Adenosinediphosphate and adenosine triphosphate are 
synthesized by megakaryocytes. The high concentration of adenosine 
diphosphate is an important mediator of platelet aggregation. 
LYSOSOMES: 
 They play a major role in lysis of thrombi. It contains β-
glucuronidase,β-galatctosidase,arylsulfatase,cathepsins and β-
hexosaminidase. Under platelet stimulation these are released very 
slowly. 
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MITOCHONDRIA: 
 They are the site for respiratory chain and citric acid cycle. They 
are approximately 7 per platelet and smaller in size compared to other 
areas. 
MICROPEROXISOMES: 
          They are the source of platelet activating factor and the size is 
about 90nm in diameter. 
COATED VESICLES: 
            They transfer the contents of the plasma into the granules and 
their number is increased with the stimulation of adenosine 
diphosphate.Its size is about 70-90 nm in diameter. 
PLATELET FUNCTION: 
           To maintain the normal haemostasis following damage to vascular 
system platelets play a main role in forming mechanical plugs. Both 
platelet adhesion and aggregation reactions are needed for the formation 
of haemostatic plug at the site of vascular injury. 
PLATELET ADHESION: 
 Adhesion of platelets to the subendothelial collagen is a step wise 
reaction. The factors which are present in the subendothelial matrix are 
collagens, vonWillebrandfactor, fibronectin, thrombospondin-1,laminins 
and microfibrils.  
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 Adhesive receptors present in the platelets are GPIb-V-IX,GPIIb-
IIIa, GPIc-IIa,GPIa-IIa and vitronectin receptor. After vascular injury 
there is exposure of subendothelial matrix to the blood and blood 
components. The first reaction is formation ofcoating ofvWFmultimer at 
the exposed surface. After that the platelets with the help of GPIb-V-IX 
binds to vWF. Then rolling of platelet occurs.[80],[81],[82] 
PLATELET ADHESION –FUNCTION OF GPIb-V-IX 
RECEPTOR: 
 It acts a link between platelets and subendothelial matrix by 
binding to von Willebrandfactor(vWF). It is a receptor for 
vWF.vWFdependent adhesion of platelet depends on the shear rate of the 
blood flow. Because of the high shear rate conformational changes occur 
in platelet receptor GPIb or in the Collagen typeI and collage type III 
helps in binding of vWF and platelets. Interaction of vWF with receptor 
causes rolling of platelets along the surface of vascular injury.  
 Bridging of cells to the subendothelial matrix occurs due to the 
rolling.Collagen plays a role in platelet adhesion.Subendothelial collagen, 
microfollicularcollagen typeIV acts as substrate for platelet adhesion and 
it functions as a platelet against.Collagen with the help of following three 
receptors making adhesion with platelets.They are GPIb-V-IX,GPIa-IIa 
and GPVI. 
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         There is another mechanism of platelet adhesion with endothelial 
cell p-selectin which is present in alpha granules and weibel –palade 
bodies of endothelial cells. Exposure of p-selectin on the surface of the 
endothelium may promote platelet adhesion by binding to GP-Ibcomplex 
on platelets.[83] 
 Various other substrates capable of binding platelets are laminin, 
thrombospondin, fibronectin, and vitronectin. 
          In various inflammatory conditions the normal preventing 
mechanisms are altered and there is adhesion of platelets 
occur.Inflammation also induces the release of molecules that enhance 
adhesion of platelets. Leukocyte adhesion occurs in the inflammation 
which also induces platelet adhesion.Interaction of p-selectin of platelet 
and p-selectin of leukocyte   occurs initially and then binding of 
fibrinogen to the leukocyte occurs.Platelet activating factor released by 
the platelets binds to the receptor known as platelet activating factor 
receptor which is present on leukocytes and later on binding of fibrinogen 
and factor x occurs. Adhesion also occurs between leukocytes and 
platelet junctional molecule-3 or GPIb. 
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SUBSTANCES PREVENTING PLATELET ADHESION TO 
ENDOTHELIUM 
1. Nitric oxide  
            It is potent vasodilator synthesised from the endothelium by the 
action of endothelial nitric oxidesynthase. Both cyclic GMP-dependent 
and independent mechanisms play a role in nitric oxide induced inhibition 
of platelet adhesion and activation. Nitric oxidemay also inhibit 
leukocyte-dependent platelet adhesion to endothelium. 
2. Prostacyclin 
            It is a prostaglandin derivative. It increases the activation of 
adenylatecyclase, thereby increasing the level of cyclic adenosine 
monophosphate, causing smooth muscle relaxation. It is a potent inhibitor 
of platelet aggregation. 
3. Ecto-adenosine diphosphatase(CD39or ADPase)    
           It is present in the endothelial cell surface membrane. Adenosine 
diphosphate is a most potent stimulator of platelets. It is metabolised by 
this enzyme ADPase 
4. Endothelial surface layer  
 It is called as glycocalyx lies between running blood and the 
endothelial membrane which is composed of glycoproteins and 
proteoglycans. This layer prevents the adhesion of platelets to the 
endothelium. 
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PLATELET SHAPE CHANGE: 
  In response to agonist’s action on platelets shape change occurs. 
Agonists are von Willibrand factor, thromboxaneA2, thrombin, adhesion, 
epinephrine, serotonin, Adenosinediphosphate, thrombospondin, 
fibrinogen, vasopressin and immunecomplexes. Upon activation a change 
in shape from disc to sphere is observed as first event. Intracellular 
calcium level in platelets is elevated and the protein gelsolin is 
activated.As a result number of actin filaments in the platelet is 
increased.Swelling of membrane cytoskeleton occurs. Then incorporation 
of plasma membrane with open canalicular system develops.  
Polimerisation of actin leads to formation of lamillopodia and filopodia. 
Two proteins present in the platelets involved in the polymerisation of the 
actin are profilin and thymosin-β4. Peripheral microtubule coil 
compressed into the center of the platelet and surrounds the granules and 
organelles.Myosin light chain kinase causes activation of myosin and 
then interaction of actin and myosin occurs. 
PLATELET SPREADING AND SURFACE INDUCED 
ACTIVATION 
 This is determined by the nature of the protein surface and the 
density of the protein.Activated platelets cause granule release and 
exposure of activated αIIbβ3receptors on the luminal surfaces of the 
platelets.This inturn recruit additional platelets.Lateral dissociations of 
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platelets developed by αIIbβ3receptors resulting in broad 
lamellopodia.Actin filament crosslinking protein filaminA form 
orgagonal network of actin filaments in lamellopodia.Calcium-dependent 
calpains also helps in spreading. 
PLATELET CONTRACTION AND SECRETION 
 Contraction of actin and myosin occurs by changes in the 
cytoplasmic calcium concentration. Cacium-calmodulin complex formed 
by the rise in calcium concentration activate myosin light-chain 
kinase.The proteins involved in platelet granule plasma membrane fusion 
are core or integral proteins,they are known as soluble N-ethylmaleimide-
sensitive factor attachment protein receptors along with accessory 
proteins. 
 Platelets Secretion (release reaction) of both granule types occurs 
soon after adhesion. Various agonists can bind platelet surface receptors 
and initiate an intracellular protein phosphorylation cascade ultimately 
leading to degranulation. 
 Platelet activation leads to the appearance of negatively charged 
phospholipids (particularly phosphatidylserine) on their surfaces. These 
phospholipids bind calcium and serve as critical nucleation sites for the 
assembly of complexes containing the various coagulation factors. 
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PLATELET AGGREGATION 
Interaction of one platelet with another is a major function of 
platelets. Release of the contents of dense-bodies is especially important 
since calcium is required in the coagulation cascade and Adenosine 
diphosphate (ADP) is a potent activator of platelet aggregation. ADP also 
begets additional ADP release, amplifying the aggregation process.  A 
configurational change in membrane GPIIb-IIIa and binding of fibrinogen 
molecules to GPIIb-IIIa receptors on adjacent platelets induces 
aggregation of platelets.[84],[85],[86],[87],[88],[89],[90] 
COAGULATION SYSTEM 
HISTORY OF COAGULATION 
 400 BC Hippocrates, the father of medicine covered the wound of 
a soldier with skin and observed that the bleeding was stopped. Once the 
skin is removed the bleeding started again. The cooling theory or blood 
coagulation was introduced by Aristotle and he found that cooling of 
blood occurs when the blood was removed from the body. No clotting 
occurs if fibres were removed.  
 In the year 1627,clots were identified in veins at body 
temperature. William Hewson noticed that air and lack of motion were 
necessary for beginning of clotting and demonstrated that the clot came 
from liquid portion of blood in the year 1770. Coagulation factors are 
assembled by scientist Paul Morawitz in 1905. He observed that in the 
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presence of calcium and thromboplastin, prothrombin was converted to 
thrombin which inturn converts fibrinogen into a fibrin clot.  
 In 1994 Paul Owren discovered the coagulation factor V and 
cofactor. Loeliger in 1952 called the cofactor as coagulation factor VII. 
Then Christmas factor or factor IX was identified. In the year 1957 factor 
X was introduced by Prower and Stuart.In 1953 factorXI was introduced 
into the coagulation system. In 1955 Ratnoff and Colopy discovered 
factor XII. In 1960 factorXII or fibrin stabilizing factor was demonstrated 
by Duckert.  In 1965 prekallikrein or fletcher factor was discovered and in 
1975 high molecular weight kininogen or fitzgerald factor was identified. 
By WilliamHewson the first whole blood clotting time was done in 1780 
and he found that the blood of a healthy normal patient clotted in 7 
minutes. In 1910 Koaguloviskosismeter was identified by Kottman. 
COAGULATION SYSTEM  
Plasma proteins in haemostasis can be divided into the following groups: 
1. Coagulation system- 
Factor I ,II ,III, IV, V, VII, VIII ,IX, X, XI, XII, XIII,   
prekallikrein andhigh molecular weight kininogen. 
2. Fibrinolytic system- 
Plasminogen,plasmin,tissue plasminogen activator,α2-
antiplasmin,plasminogen activator inhibitor-1 and plasminogen 
activator inhibitor-2. 
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3. Inhibitor system- 
Protein C,protein Sand antithrombin-III. 
COAGULATION SYSTEM 
 Coagulation is a host defence system that maintains the integrity 
of the high pressure closed circulatory system. It is one of the important 
components in the normal haemostasis. It is a cascade of events in which 
inactive substances are activated ending in thrombin formation which in 
turn converts fibrinogen into fibrin monomers. Subsequently these 
monomers are polymerised in which platelets and other cells are encased 
and finally secondary haemostatic plug is formed. 
 Every step of coagulation cascade consists of activated 
coagulation factor that is enzyme, proenzyme form of coagulation factor 
that is a substrate and a reaction accelerator that is called as cofactor. All 
the above are combined with calcium ions on the phospholipid surface. 
Usually the coagulation occurs over the surface of activated platelets or 
endothelium. 
 Proenzymes called zymogens grouped into phospholipid bound 
zymogens and surface bound zymogens. Phospolipid bound zymogens 
are proteins which are vitamin k dependant.[91] 
VITAMIN K DEPENDANT COAGULATION FACTORS 
 Factor VII 
 Factor X 
 31 
 Factor II 
 Factor IX 
 Protein C 
 These proteins require vitamin K for their synthesis. They have 
10-12 residues of γ-carboxyglutamic acid. This carboxylic reaction 
occurs by the help of membrane bound γ –carboxylase,which is located 
on endoplasmic reticulum. By this enzyme there is addition of γ-carboxyl 
group to the sialic acid residue group which are present in these 
zymogens. This carboxylation reaction enable these zymogens to bind to 
cell membrane and phospholipids followed by their activation there by 
helps in the formation of clot. 
SURFACE BOUND ZYMOGENS: 
       They are- 
 Factor XII 
 Prekallikrein 
 Factor XI 
 They are also called contact factors because factor XII 
autoactivates the intrinsic pathway of coagulation when it is exposed to 
thrombogenic surfaces. This phenomenon of autoactivation of factor XII 
is used in the laboratory test Activated Partial Thromboplastin 
Time(APTT). 
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COFACTORS: 
       They are also called as reaction accelerator. They are 
 High molecular weight kininogen 
 Factor VIII 
 Factor V 
 Fibrinogen  
 Protein S 
 They act as a receptor for coagulation proteins. For example 
factor VIIIa acts as a receptor for factor IXa and factor Va is a receptor 
for factor Xa and high molecular weight kininogen functions as receptor 
for prekallikrein. These cofactors help in the activation of coagulation 
cascade. They also function as substrates of enzymes in coagulation 
events. 
COAGULATION SYSTEM 
COAGULATION:  
 There are number of proteins thatparticipate in normal 
coagulation finally leading to form fibrin clot. As per international system 
of nomenclature the coagulation factors are designated by Roman 
numerals from I to XIII. [92] 
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BLOOD COAGULATION FACTORS:  
 
FACTOR SYNONYM ACTIVE FORM 
I Fibrinogen Fibrin subunit 
II Prothrombin Serine protease 
III Tissue factor, thromboplastin Receptor/cofactor 
IV Calcium  
V Labile factor,proaccelerin Cofactor 
VI 
F VI has been determined to be activated 
form of FV and the term FVI is no longer 
used. 
Serine protease 
VII Stable factor  
VIII Antihaemophilic factor or globulin Cofactor 
IX 
Christmas factor, Plasma thromboplastin 
components 
Serine protease 
X Stuart-Prower factor Serine protease 
XI Plasma thromboplastin antecedent Serine protease 
XII Hageman factor Serine protease 
XIII Fibrin stabilising factor, Lakilorand factor Transglutaminase 
Fletcher  
factor 
Prekallikrein Serine protease 
Fitzgerald 
factor 
High molecular weight kininogen Cofactor 
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FIBRINOGEN: 
 It is a soluble glycoprotein synthesised from liver hepatocytes. Its 
level is highest among the coagulation proteins, ranges from 200-
400milligram/dL in which 75% are present in the plasma and 25% are 
distributed in the lymph and interstitium. Molecular weight is 340 
kilodaltons.  
 It is made up of 6 polypeptide chains. Two Aα chains, two Bβ 
chains and two γ chains are linked by disulphide bonds.  There are two 
domains, domain E and domain D. Domain E is formed by amino 
terminal of all chains which participates in the formation of cross linking 
of chains. D domain is formed by carboxy terminal regions of Bβ and γ 
chains which is meant for protein- protein interactions. In the α and β 
chains there is a small peptide sequence which prevents the formation of 
fibrin polymers. Normal half-life is 3-5 days. 
 In the coagulation process formation of fibrin from fibrinogen 
takes place in various stages. The N terminals of the fibrinogen α and β 
chains are to form protofibrils which inturn associate latter to form fibrin 
fibres. The above said reaction is catalysed by thrombin. The fibrin 
strands are cross linked by factor XIII to form a clot. Factor XIIa 
stabilises fibrin further by incorporation of the fibrinolysis inhibitors 
alpha- 2- antiplasmin and thrombin activatable fibironlysis inhibitor, 
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procarboxypeptidase and binding to several adhesive proteins of various 
cells. 
 Both the activation of factor XIII by thrombin and plasminogen 
activator are catalysed by fibrin. Fibrin binds the activated coagulation 
factor Xa and thrombin and entraps them in the network of fibres. Thus 
functioning as a temporary inhibitor of these enzymes it can form bridges 
between platelets by binding to their GPIIb/IIIa surface membrane 
proteins.  
PROTHROMBIN: 
 It is a single polypeptide glycoprotein produced from the liver 
having 579 amino acids with a molecular weight of 72,000daltons. The 
gene for prothrombin and thrombin is located on chromosome number 
11. Normal concentration of prothrombin in the blood is approximately 
100µg/ml. Half-life of prothrombin is 3 days.  
 After synthesis it undergoes post translational modification by 
vitamin K dependant reaction. In this reaction glutamic acid in the 10th 
position is replaced by γ carboxy glutamic acid, it is called as γ 
carboxylation reaction. 
 Prothrombin is converted into thrombin by the action of 
prothrombinase complex. In this complex factor Xa activity is greatly 
enhanced by binding to activated factor V and calcium. Prothrombin is 
first converted into meizothrombin and then to α thrombin. 
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 α thrombin  is a potent activator of platelet and induces the release 
of contents of both α and dense granules. From the α granules many 
adhesive and procoagulant factors are released and from the dense 
granules adenosine diphosphate is released. α thrombin also induces the 
exposure of anionic surface of platelets. It cleaves the fibirinogen into 
fibrinopeptide A and fibrinopeptide B. It activates factor XI to XIa, factor 
VII to VIIa, factor V to Va and factor XIII to XIIIa. By combining with 
thrombomodulin it activates protein C. The activated protein C 
inactivates factor Va and VIIIa. A serine protease inhibitor antithrombin 
III blocks the action of thrombin.  
 Meizothrombin is a potent vasoconstrictor and activates factor XI 
and factor V and also augments α thrombin formation by activating factor 
XII. 
Thrombin activatable fibrinolysis inhibitor: 
 It is otherwise known as plasma carboxypeptidase B, synthesised 
by the liver. It circulates in the plasma as a plasminogen bound zymogen. 
It is activated bythrombin/thrombomodulin complex. It reduces the 
fibrinolytic activity by removing the binding site for plasminogen. [93] 
TISSUE FACTOR: 
 Tissue factor, also called platelet tissue factor, factor III, 
thromboplastin, or CD142 is a protein present in subendothelial 
distribution in all tissues and in high concentration in brain, placenta and 
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lungs and also present in leukocytes . It is a non-enzymatic cofactor for 
factor VIIa in the extrinsic tenase complex. It has got a high affinity 
receptor for factor VII. Gene for this is located on chromosome 1p21-22. 
It is a single chain glycoprotein.  
 Tissue factor can bind either factor VII or factor VIIa in the 
presence of calcium. This extrinsic tenase complex activates factor IX 
and X thereby extrinsic pathway of coagulation is initiated. 
FACTOR V: 
 It is otherwise known as proaccelerin or labile factor.  It is a 
coagulation protein synthesised from the liver and in the platelets as a 
large single chain glycoprotein. In the platelets it is presented in the α 
granules that constitutes 25% of the total factor V. The average plasma 
concentration is 20 nmol/L. Its molecular weight is 330 kilodaltons. Gene 
for this factor is present on chromosome-1q23. In contrast to other factors 
it is not enzymatically active and it acts as a cofactor. Plasma half-life is 
12 hours.  
 It binds to activated platelets. α thrombin cleaves the single chain 
molecule into two chains, one is called light and the other one is called 
heavy. They are non-covalently bound to each other by calcium. Factor 
Xa cleaves factor V and produces active factor Va. Compared to α 
thrombin the effect of cleavage of factor Xa on factor V is less efficient. 
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Other factors like platelet calpain, cathepsin G, and human neutrophil 
elastase will also activate factor V partially. 
 It forms prothrombinase complex and stabilises the complex and 
helps in inactivation of prothrombin. On the cell membrane prothrombin 
is converted into thrombin with the help of activated factor X and 
activated factor V. In this reaction factor Va acts as a cofactor for factor 
Xa. It helps to anchor the factor Xa on the membrane surface of the 
platelets. 
 Thrombomodulin combines with thrombin and activates protein 
C. Protein C when it gets activated causes degradation of factor Va, 
thereby inhibiting the coagulation. 
 Lack of factor V in factor V Leiden mutation clotting will not 
occur. It is a very rare inherited coagulopathy. 
FACTOR VII: 
 The gene for factor VII is located on chromosome 13. It is a 
single chain zymogen of a molecular weight of 50,000 daltons consists of 
406 amino acids.It is synthesised mainly in the liver. It is also called as 
proconvertin with the plasma concentration 10 nmol/L. It binds to the 
membrane cofactor, tissue factor and helps in initiation of extrinsic 
pathway of coagulation. Among the coagulation factors it has very short 
half-life of about 3-6 hours.  
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 Activation of factor VII to factor VIIa is occurred by α thrombin 
factor IXa, factor Xa, autoactivation of factor VIIa and factor XIIa. After 
activation single chain is cleaved into light and heavy chain.  
 Tissue factor is found on the outside of blood vessels. It is 
normally not exposed to the bloodstream. Upon vessel injury, tissue 
factor is exposed to the blood and circulating factor VII. Factor VII 
combines with integral membrane protein tissue factor to form extrinsic 
tenase complex. The extrinsic tenase complex contains activated factor 
VIIa, tissue factor, membrane surface and calcium which is extrinsic to 
the plasma environment. This complex activates factor X into Xa and 
factor IX into IXa. 
FACTOR VIII: 
 FVIII is a non-enzymatic glycoprotein procofactor, synthesized 
and released into the bloodstream by the vascular, glomerular, and tubular 
endotheliumand sinusoidal cells of the liver. The gene that codes for 
FVIII is located on the long arm of the chromosome X. It is present in the 
plasma in combination with multimeric protein von Willebrand factor. 
This combination with vWF acts to regulate the plasma concentration and 
stabilisation of factor VIII. Its molecular weight is 2,80,000 daltons. It is 
secreted as two-chain heterodimers. It has copper ion binding site A 
domain, which is important for protein function. It also contains binding 
sites for vWF, anionic phospholipids, factor IXa and factor X.  
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 α thrombin activates factor VIII into factor VIIIa. After activation 
it binds to factor IXa to form calcium and membrane dependant complex 
called as the intrinsic tenase complex. This complex activates factor Xa.  
VON WILLEBRAND FACTOR: 
 vWF is a large multimeric glycoprotein present in blood plasma 
and produced from the  Weibel-Palade bodies of endothelium, α-granules 
of platelets, and subendothelial connective tissue. It is synthesized as 
prepro molecule which undergoes extensive post translational 
modification to form mature vWF protein. The vWF gene is located on 
chromosome 12. Average plasma concentration is 10 µg/ml. Its level is 
increased with pregnancy, surgical trauma and stress. Individuals with 
type O blood group have lower level of vWF than type A,B, or AB blood 
groups.  
 The vWF monomer contains 2050 amino acids.The domains 
which are present in the vWF factor are D,C1,A1,A3 and cysteine knot 
domain. D domain has got binding site for factor VIII whereas C1 
binding domain binds to platelet receptor GPIIb-IIIa. The A1 domain 
binds to platelet GPIb-receptor, heparin and collagen. The A3 domain 
binds to collagen. 
 Factor VIII is stabilised by vWF .It undergoes rapid degradation 
when it is not bound to vWF and half-life is prolonged when it is bound 
to vWF. Factor VIII is released from vWF by the action of thrombin. 
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vWF binds to platelet GPIb when it forms a complex with GPIX and 
GPV, thereby promoting platelet aggregation and adhesion. vWF binds to 
other platelet receptors when they are activated and also binds to 
collagen. vWFmutimers produced by the endothelial cells are large and 
they bind to and agglutinate platelets in the presence of high shear stress.  
FACTOR IX: 
 It is also called as Christmas factor or hemophilia B factor or 
plasma thromboplastin component. 
 It is a glycoprotein consists of 415 aminoacids produced as 
zymogen in the liver. Factor IX gene is located on the chromosome X 
near factor VIII gene. It is a vitamin K dependent coagulation factor 
which undergoes gamma carboxylation in the presence of vitamin K. 
 It is cleaved by factor XIa or factor VIIa to produce two chains 
which are linked by a disulfide bridge. This cleavage occurs in two 
stages, the 1st stage forms factor IXα and then the 2nd stage forms IXa. It 
forms intrinsic tenase complex with its cofactor VIIIa, calcium and 
platelet membrane surface. This complex activates factor X to Xa. 
DOMAINS: 
Factor IX contains four protein domains. They are the Gla domain, 
two random copies of the EGF domain and a C terminal trypsin like 
peptidase domain. 
 42 
Gla domain is for calcium binding, the EGF domain for tissue 
factor binding and platelet binding sites. The C-terminal trypsin like 
peptidase is for catalytic cleavage. The intrinsic tenase complex is more 
efficient in activation of factor X to factor Xa than extrinsic tenase 
complex. Factor IX is inhibited by antithrombin III. 
FACTOR X (STUART- PROWER FACTOR): 
 It is also known as prothrombin, thrombokinase. It is a Vitamin K 
dependant glycoprotein produced from the liver. It is a serine 
endopeptidase. Its molecular weight is 59,000 Daltons. Plasma 
concentration is 170 nmol per litre.It contains two chains linked by 
disulfide bond. Its half-life is 40-45 hours. 
` Activation of factor X is by extrinsic tenase complex and intrinsic 
tenase complex. Factor Xa cleaves prothrombin in two places, produces 
active thrombin. This occurs after the formation of prothrombinase 
complex.Factor Xa is activated by protein Z dependant protease inhibitor. 
FACTOR XI: 
                  It is the member of contact pathway.It is also called as Plasma 
thromboplastin antecedant.It is a Zymogen form of factor XIa, a serine 
protease. Factor XI is encoded by the FXI gene. Its average concentration 
is 30nmol/L.It contains 607 aminoacids and circulates as homodimer. 
Plasma half-life is 52 hours. Its gene is located on chromosome number 4. 
It is present in plasma and platelets. It has 4 apple domains, apple 1 to 
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apple 4. In the circulation it forms complex with HMWK. Apple 1 
domain binds with anionic surfaces and α thrombin and prothrombin. The 
apple 2 and apple 3 both bind to factor IX. 
 Factor XI is activated into factor XIa by factor XIIa, thrombin and 
factor XIa itself. Factor XIa activates factor Xa by cleaving peptide 
bonds. Factor XIa is inhibited by protein Z dependant protease inhibitor. 
FACTOR XII  
 It is a plasma protein involved in blood coagulation, also named 
as Hageman factor. It is a zymogen precursor of factor XIIa. Average 
normal concentration in the plasma is 40 microgram per ml. In post-
menopausal women with hormonal replacement therapy and in pregnant 
women the level of factor XII is increased. Structurally it consists of 596 
amino acids in which a heavy chain and a light chain bound by disulfide 
bond. Its molecular weight is 18,000 Daltons. At the tip of long arm of 
chromosome 5 the gene for factor XII is present. It initiates coagulation 
on contact with thrombogenic surface and hence it is also called as 
contact factor.  
 Factor XII deficiency is not associated with bleeding tendency 
and hence its role in haemostasis is not clear. There are some studies in 
which mice with factor XII deficiency are protected from arterial 
thrombosis. Factor XII initiates autoactivation when it is exposed to 
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negatively charged surfaces like glass, kaolin and interaction with 
hydrophobic surfaces.  
 In our body it is usually activated by a cell membrane associated 
proteinase. Factor XII, prekallikrein and high molecular weight kininogen 
form a complex on anionic phospholipids of the cell membrane.This is 
the starting point of intrinsic pathway of coagulation. The prekallikrein is 
divided to form the enzyme kallikrein. This in turn activates factor XII. In 
addition to this activation, plasmin also activates factor XII and the factor 
XII is cleaved to form alpha factor XIIa. This cleavage causes exposure 
of the active site of factor XIIa and factor XIIa can bind with negatively 
charged surfaces to activate factor XI and prekallikrein. 
 Factor XIIa activates factor XI and prekallikrein. It also activates 
the complement system and down regulates Fc receptor on the 
macrophages and monocytes to release interleukin 1 and interleukin 6. It 
stimulates neutrophils.Hence there is a link between inflammation and 
coagulation. 
       Factor XII deficiency is a very rare autosomal recessive condition in 
which there is no abnormality observed in the haemostatic system.  
FACTOR XIII OR FIBRIN STABILIZING FACTOR: 
 It is also known as Laki-Lorandfactor in 1948 by scientist. It 
functions as transglutaminase. It circulates as a heterotetramer composed 
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of two A-chains and two B-chains. Gene for A-chains situated on 
chromosome 6 and for B-chains on chromosome 1. 
 Bone marrow is the main site of synthesis for the plasma factor 
XIII-A chain. Intracellular factor XIII is present in platelets, 
megakaryocytes and monocytes. It is a heterodimer which has two 
catalyticsubunits,A subunithas enzymatic activity and B subunit act as a 
carrier. 
 Factor XIII is converted to factor XIIIa in the presence of cofactor 
calcium. Factor XIII uses cysteine for catalysis. Fibrinogen is converted 
into fibrin by thrombin, then activated factor XIIIa acts on fibrin to form 
an insoluble clot. 
 Substrates for factor XIII include fibrin, fibrinectin, α2 plasmin 
inhibitor, collagen, vitronectin, vWF, actin, myosin, factor V and 
thrombospondin. 
PROTEIN C: 
 It is also called as antiprothrombin II A and blood coagulation 
factor XIV.It is a Zymogen form of activated protein C. Its half-life is 8 
to 10 hours. Gene is located on chromosome Z. Synthesised in the liver as 
prepro sequence of having 42aminoacids which is a single chain 
polypeptide. 
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 Light and heavy chains are linked by disulfide link. Protein C is 
activated when it binds to thrombin in the presence of thrombomodulin 
and endothelial protein C receptors. 
PREKALLIKREIN (FLETCHER FACTOR): 
 In 1965 Hathaway described this factor and in the year 1973 this 
factor is named as “Fletcher factor’’. It is a serine protease precursor of 
kallikrein. In combination with high molecular weight kininogen 
Kallikrein activates kinins. Activated factor XII is needed for production 
of kallikrein from prekallikrein. 
 Plasma prekallikrein is a glycoprotein, synthesised in the liver and 
secreted into the blood as a single polypeptide chain.Gene is located on 
chromosome 4 close to factor IX gene. Normal concentration in the 
plasma is 486 nmol/L. 3/4 of the total concentration forms complex with 
high molecular weight kininogen and 1/4 of it is free in the plasma. It 
participates in the surface dependant activation of coagulation, 
fibrinolysis, kinine generation and inflammation.  
 Prekallikrein is activated by two ways. In one way by β-factor XII 
without an anionic surface and the other one is in combination with 
activated factor XII and with the help of cofactor high molecular weight 
kininogen on the anionic surface. In both ways cleavage occurs between 
arginine and leucin. This reaction also occurs when prekallikrein is bound 
to high molecular weight kininogen without the help of factor XIIa. 
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 Prekallikrein consists of a heavy chain which is for surface 
dependant procoagulant activity and the light chain containing active site 
or catalytic domain. Plasma prekallikrein deficiency causes prolonged 
activated partial thromboplastin time in patients.  It acts as a link between 
coagulation and fibrinolytic system. 
KALLIKREINS: 
       Plasma kallikrein produces kinins from kininogens for regulation of 
blood pressure and activation of inflammation. It helps in the formation 
of plasmin from plasminogen. Kallikrein with factor high molecular 
weight kininogen activates factor XII to factor XIIa and proteolysis of 
factor XIIa to β- factor XII and this reaction occurs with anionic surface. 
Bradykinin is produced from high molecular weight kininogen by the 
action of kallikrein. Bradykinin induces the endothelial cell for the 
formation of prostacyclin from arachidonic acid metabolites which causes 
dilatation of vascular system and reduction of blood pressure. Kallikrein 
activates neutrophils and stimulates elastase release. C1 inhibitor, α 
macrogloblin and antithrombin III regulates the activity of kallikrein. 
HIGH MOLECULAR WEIGHT KININOGEN: 
 It is a circulatory protein which participates in the initiation of 
blood clotting, generation of bradykinin and kinins.  It is an alpha 
globulin with 6 functional domains. It is a single chain polypeptide 
containing 626 amino acids. Heavy chain contains 1,2 and 3 domains and 
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the light chain contains 5 and 6 domains whereas the domain 4 links the 
light and heavy chains.  
FUNCTIONS OF DOMAINS: 
Domain 1 It has low affinity calcium binding capacity. 
Domain 2 Inhibits cysteine protease such as cathepsin. 
Domain 3 Inhibits cysteine protease and it will have platelet and  
   endothelial cell binding. 
Domain 4 It is for bradykinin production and it also inhibits α- 
   thrombin. 
Domain 5 It binds to heparin and cell binding and also binds to  
negatively charged surfaces. 
Domain 6 It has prekallikrein and factor XI binding capacity. 
MECHANISM OF BLOOD COAGULATION: 
 Blood coagulation involves a cascade of events in which 
proteolysis of circulating precursor proteins ends in the generation of 
thrombin. This thrombin converts fibrinogen which is a soluble plasma 
protein into insoluble fibrin. Platelets are entrapped in the fibrin mesh at 
the site of vascular injury and platelet aggregation occurs into the fibrin 
mesh and then finally the unstable platelet plugs are converted into stable 
haemostatic plugs. There are many coagulation factors which are 
involved in this coagulation cascade. 
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INITIATION OF COAGULATION: 
 As a result of vascular injury, membrane bound tissue factor is 
exposed. Tissue factor interacts with active form of factor VIIa. After that 
activation of both factor IX and factor X occurs by the activation of 
complex which consists of factor VIIa and tissue factor. The activated Xa 
forms small amount of thrombin from prothrombin. This reaction initiates 
coagulation. 
AMPLIFICATION: 
 The small amount of thrombin formed in the initial stage of 
coagulation leads to amplification of coagulation system. In this phase 
intrinsic tenase complex is formed by factor IXa and VIIIa in the 
presence of calcium over the phospolipid surface. This process activates 
factor Xa which then in combination with Va, phospolipid and calcium 
forms the prothrombinase complex and results in the explosive generation 
of thrombin which acts on fibrinogen to form the fibrin clot. 
COAGULATION PATHWAYS: 
 It is divided into extrinsic, intrinsic and common pathways. 
INTRINSIC PATHWAY: 
 Contact of plasma with negatively charged surface is provided by 
the subendothelium of a damaged vessel. Following this contact initiation 
of intrinsic pathway occurs by conformational change in factor XII which 
is converted into factor XIIa.  
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 This active form of XIIa converts prekallikrein to kallikrein and 
inactive factor IX to factor IXa. In the presence of high molecular weight 
kininogen, Factor XIa cleaves factor IX to give factor IXa. For this 
reaction calcium and phospholipid are needed. Factor X is converted into 
Xa by means of factor IXa complexes with factor VIII, phospholipid and 
calcium. Factor VIII is activated by thrombin and also by factor Xa. 
Factor VIII acts as a cofactor and accelerates the reaction.  
EXTRINSIC PATHWAY: 
 In this pathway as a result of tissue injury tissue factor is released. 
This tissue factor complex with factor VII and in the presence of calcium 
leads to activation of factor X and factor IX. Factor Xa and thrombin 
converts the single chain form of factor VII to two chain form which has 
got enzymatic activity. This reciprocal activation of factor VII leads to 
auto amplification of the reaction.  
COMMON PATHWAY: 
 This pathway starts with activation of factor X. Both intrinsic and 
extrinsic pathway generates factor Xa. This activated form of factor X 
complexes with factor V, phospholipid and calcium. This complex 
converts prothrombin to thrombin. Either thrombin or factor Xa activates 
factor V which functions as a cofactor.  
 Thrombin acts on fibrinogen which contains α and β chains to 
remove fibrinopeptides A and B. Thereby the fibrin monomer is formed. 
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Polymerisation of fibrin monomers occurs spontaneously by the 
formation of non-covalent bonds which are end-to-end and side-to-side. 
In this way the fibrin polymer is formed. Factor XIIIa which is formed 
from inactive factor XIII by the action of thrombin. It mediates the 
formation of covalent bonds between adjacent polypeptide chains in the 
presence of calcium. This cross linking of fibrin monomers forms stable 
clot. 
FIBRINOLYTIC SYSTEM: 
PLASMINOGEN: 
 It is synthesised in the liver and has a molecular weight of 92 Kilo 
daltons. It is composed of a single chain and there are two forms Glu-
plasminogen which is larger having N-terminal glutamic acid and other 
form is Lys-plasminogen. Lys-plasminogen is formed in the circulation 
by plasmin cleavage and it rapidly binds to fibrin via lysin binding sites. 
When plasminogen is activated it is converted into active two chain 
plasmin with a serine active site on heavy chain that is connected to light 
chain by disulphide bonds.  
 Plasmin causes proteolysis of fibrinogen and fibrin. Plasmin also 
degrades other proteins including factor VIII, factor V, vWFand others. 
The cleavage of fibrinogen and fibrin leads to the formation of fibrin 
degradation products. Fibrinogen on degradation first gives largest 
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fragment X. Fragment X gives rise to fragments Y and D. Fragment Y is 
further proteolysed to give rise to a second fragment D and fragment E.  
TISSUE PLASMINOGEN ACTIVATOR: 
 It is a physiological activator of plasminogen synthesised in 
endothelial cells which has got high affinity for plasminogen. Its 
molecular weight is 68,000 Daltons. In the circulation it usually 
complexes with its inhibitor plasminogen activator inhibitor-1. During the 
process of coagulation this complex is separated and free tissue 
plasminogen activator combines with fibrin so that its activity is 
enhanced. Compared to single chain form, two chain form has got three 
fold higher activity. 
UROKINASE PLASMINOGEN ACTIVATOR: 
 It is found in the kidney, urine and fibroblast-like cells and it is a 
single chain zymogen. It also activates plasminogen. 
PLASMINOGEN ACTIVATOR INHIBITOR-1: 
 Synthesised by the endothelial cells and acts as a physiological 
inhibitor of tissue plasminogen activator. Plasminogen activator inhibitor-
2 which is found in plasma and plasminogen activator inhibitor-3 also 
inhibit tissue plasminogen activator. 
ANTIPLASMIN: 
  It is a physiological inhibitor of plasmin synthesised by the liver 
with molecular weight of 58,000 Daltons. It inhibits plasminogen binding 
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to fibrin and inhibits the proteolytic activity of plasmin. By the action of 
factor XIIIa it binds to fibrin in a covalent manner. By binding to fibrin 
antiplasmin competitively inhibits the binding of plasminogen to fibrin.  
ENDOTHELIUM: 
 Normal vascular endothelium is one cell thick, separating the 
blood and vascular smooth muscle. It lines the interior surface of the 
blood vessels forming an interface between circulating blood and the rest 
of the vessel wall. 
 Endothelial cells are exposed to shear stress of the blood and the 
interaction between the cells and the vascular wall. It regulates the 
fluidity of blood through thrombo resistance and profibrinolytic potential. 
It regulates vascular permeability and fragility. It plays a major role in 
maintaining the lumen patency in the vascular system. Thrombo 
regulatory compounds are produced from endothelial cells. 
 In thrombus formation these compounds control platelet and 
vascular reactivity. They are eicosanoids, nitric oxide,endothelin and 
CD39/ENTPDI (ecto-nucleoside triphosphate diphosphohydrolase). 
EICOSANOIDS 
They are also called prostaglandins. They are produced from the 
essential fatty acids in diet. The main prostaglandin from the endothelium 
is prostacyclin (PGI2). Biosynthesis of PGI2 occurs by two methods. In 
rapid method agonists activate the phospholipase C.Increased 
 54 
intracellular calcium brings the phospholipase A into the endoplasmic 
reticulum. It produces vascular relaxation, cytokine production and it 
blocks platelet reactivity. 
 Seventransmembrane G-protein coupled receptor that couples 
with adenyl cyclase which is present in platelet is type I prostaglandin 
receptor .This receptor activates protein kinaseA which inturn inhibit 
platelet activation and platelet recruitment.[94],[95] 
NITRIC OXIDE: 
 It is a gas produced from vascular endothelial cells when 
vasodilators binds to the receptors over the endothelial cell membrane. It 
is short bind substance. It blocks the agonists induced platelet reactivity. 
It increases the cyclic guanosine monophosphate by acting on 
guanylatecyclase and inturn produces vascular relaxation and inhibition 
of platelet function. It reduces the expression of P-selectin on the platelets 
and inhibit the conformational changes in β2 integrin protein IIb-IIIa 
which is required for fibrinogen cross binding.[96],[97],[98],[99] 
ENDOTHELIN: 
 It is a polypeptide regulating vascular tone by binding to a G 
protein coupled receptor on the cells of smooth muscle.It is produced 
from the precursor preproendothelin I by the converting enzyme into 
endothelin-I.Binding with receptor increases the calcium in the cytoplasm 
resulting in vasoconstriction.  
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ENDOTHELIAL CELL CD39/ENTPDI (ecto-nucleoside 
triphosphate diphosphohydrolase) 
 It is present in endothelial cells and leukocytes .It prevents further 
platelet activation and recruitment by metabolising adenosine 
diphosphate in the platelets.  It has a good therapeutic application. 
LATE THROMBO REGULATING SUBSTANCES: 
 They prevent excessive thrombin production. They also promote 
lysis of thrombi in the blood vessels. Anti-thrombin inhibits thrombin and 
factor Xa in the circulation. 
 It acts as natural anticoagulant. Heparin proteoglycans from 
endothelium play as cofactors for antithrombin. Tissue factor pathway 
inhibitor inhibits tissue factor and factor VIIIa complex. Direct 
anticoagulant effect on thrombin is mediated by thrombomodulin and 
protein C system. Endothelial cells control the formation of plasmin from 
plasminogen and also synthesise and secrete components of fibrinolytic 
system.Thromboregulatory system maintains the fluidity of the blood by 
interaction of blood cells and cells in the endothelium.    
ROLE OF ENDOTHELIUM IN REGULATING CELL 
CIRCULATING FUNCTION 
 Cell-cell adhesion is dependent on interaction of cell adhesion 
molecules. P-selectin is present in platelets and in the weibel-palade 
bodies of endothelial cells. They are glycoproteins upon activation of 
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endotheleial cells they are expressed on the cell surface and binds to the 
counter receptors on circulating platelets and neutrophils. 
 Cytokines such as tumor necrosis factor α and γ, Interleukin-I and 
Interleukin-4 act on endothelial cells and make the cells proadhesive. 
Thus the endothelium regulates the migration of platelets, leukocytes and   
monocytes. 
INHIBITORS OF COAGULATION: 
Tissue factor pathway inhibitor (TFPI): 
 It is synthesized by micro vascular endothelial cells, monocytes 
and macrophages. Mostly they are bound to lipoproteins in the 
circulation. The free form is most active compared to bound form. 
 Tissue factor pathway inhibitorcontains three kunitz type protease 
inhibitor domains. The second kunitz domain inhibits the factor Xa. This 
action is needed for the action of first kunitz domain to inhibit factor 
VIIa/ tissue factor complex. The third kunitz domain binds to endothelial 
cell glycosaminoglycans and released by heparin. 
ANTITHROMBIN:  
 It is the most important physiological serine protease inhibitor 
otherwise known as serpins. It is a single chain glycoprotein synthesized 
in the liver. It acts as a suicide substrate for their target protease through a 
surface exposed structure termed as reactive site loop.Anti-thrombin 
inhibits activated factor IX, activated factor X, activated factor XII and 
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thrombin. Heparin like substances enhances the anti-thrombin activity. It 
is a serine protease cofactor III. 
ACTIVATED PROTEIN C: 
 It causes inactivation of factor Va and VIIIa by irreversible 
proteolysis. Protein C also enhances the fibrinolysis.  
COFACTORS FOR ACTIVATED PROTEIN C: 
Protein S: 
 It acts as a cofactor for activated protein C. 
Factor V: 
 It enhances the action of activated protein C against factor S. It 
acts synergistically with factor V for the above reaction. High density 
lipoproteins and glycosphingolipids also act as cofactors for activated 
protein C. 
TISSUE FACTOR PATHWAY INHIBITOR 
 It forms quaternary complex with factor VIIa, Tisssue factor and 
Factor Xa and causes neutralisation.  It is a powerful inhibitor of FVIIa-
tissue factor complex and it is serine protease inhibitor of Kunitz-type. 
SCREENING TESTS FOR HEMOSTASIS 
TESTS TO ASSESS THE PLATELET FUNCTION 
 Bleeding time 
 Platelet count  
 Platelet function analyser-100and Platelet aggregation studies 
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BLEEDIND TIME: 
 By doing bleeding time,the function of the platelets are assessed 
and also the vascular components.So it is a measure of primary 
haemostasis.It is time taken for bleeding to stop after the puncture is 
produced on the skin surface allowing the free flow of blood 
 Increased bleeding time indicates impairment of platelet function 
or impaired contracture of the vasculature or both.  
Methods for testing the bleeding time are 
1. IVY’S METHOD 
2. DUKE’S METHOD 
3. TEMPLATE METHOD 
IVY’S METHOD  
 Principle: under fixed pressure three standard punctures are 
produced on the volar aspect of the forearm by using microlancet and the 
average time taken for the bleeding to stop from the puncture sites is 
measured. 
INSTRUMENTS USED: 
1. Sphygmomanometer 
2. Sterile disposable microlancet –having cutting depth of 2.5 mm 
and width of 1.0mm 
3. Stop watch 
4. Filterpaper 
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PROCEDURE: 
 A Sphygmomanometer cuff is put around the patient’s upper arm 
and pressure is fixed to 40 mm Hg by inflating the cuff. 
 With antiseptic 70% ethanol ,the dorsal surface of the forearm is 
cleaned 
 Three punctures are done by using microlancet at 5-10 cm apart. 
 One stopwatch is used for each puncture.As soon as the puncture is 
made the stopwatch is started. 
 By using the filter paper bloodoozingfrom the wound is blotted. 
Direct touching of the edges of the wound should be avoided. 
 The timer is stopped when there is no stains in the filter paper.  
 Time taken for bleeding to stop from all three puncture wound is 
noted. The average time is recorded  as the bleeding time   
 Sterile adhesive strip is placed over the sites of puncture. 
 Normal bleeding time :2-7 minutes. 
Conditions producing prolonged bleeding time are  
 Low platelet count  
 Platelet function disorders 
 Von Willebrand disease 
 Disorders of blood vessels. 
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DUKE’S METHOD 
 It is done by puncturing of ear lobe. Since it produces large 
haematoma it is not in use. 
TEMPLATE METHOD  
 In this method larger cut is made with the help of surgical blade 
and the wound is 5mm long and 1mm deep. It produces a large scar. 
PLATELET COUNT 
             Platelet count can be done by manual method or by using of 
automated haematology analyser.  
MANUAL COUNT:   
            Blood is collected from the vene puncture and the anticoagulant 
used is dipotassium salt of ethylene diaminetetraacetic acid (EDTA). 
EDTA is a choice of anticoagulant because it chelates the calcium ions 
and minimize platelet adherence and clumping.  
            By doing platelet count estimation the factors to be considered are  
1. They should be separated from the dust particles or fragments of 
red blood cells. 
2. They are very small in size. 
3. They will have a tendency to aggregate together or adhere to the 
glass ware. 
4. Capillary blood should be avoided since platelets adhere at the site 
of wound and gives false low platelet count. 
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METHODS: 
 Anticoagulated venous blood is thoroughly mixed with diluent in 
the ratio of 20:1. 
 Charge the improved Neubauer counting chamber. 
 Place the mounted counting chamber inside a moist chamber and 
leave it undisturbed for 20 minutes. This is for settling of platelets 
and for the prevention of drying of fluid. 
 Platelet is counted by using microscope with 40x objectives in the 
central large square. Platelets are round or oval, small bluish 
brightly refractile fragments. 
 Problems encountered in the peripheral smear examination of 
platelets are platelet clumps, platelet satellitism on white blood cells and 
poor smearing. 
AUTOMATED METHOD: 
 Principle used by this method is principle of aperture impedance. 
This method was first introduced by Coulter Electronics and so it is called 
as coulter principle. 
TESTS TO ASSESS THE COAGULATION SYSTEM 
1. Clotting Time 
2. Prothrombin Time 
3. Activated partial thromboplastin Time 
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CLOTTING TIME: 
Methods: 
Wright’s capillary tube method 
 Under sterile precautions a deep prick is made in the finger tip. 
Time is noted when bleeding starts by starting the stop watch. 
  The blood drop at the fingertip is touched with one end of the 
capillary tube which is kept tilted downwards. 
  The tube is filled by capillary action. 
  After about two minutes small lengths of the tube are snapped off 
at intervals of 15 seconds and each time it is noted whether the 
fibrin thread is formed between the ends of snapped tube. 
 When the fibrin thread is first seen time is noted 
Lee and White method 
 Two unsiliconised glass tubes with 10mm external bore should be 
prewarmed by keeping at 37° C bath. 
 Blood is drawn from anticubital vein by a clean venepuncture. As 
soon as blood enters the syringe two stop watches are started. 2-2.5 
mL of blood is collected and 1mL of blood is poured into each tube 
after removing the needle.  
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 Tubes are kept at 37°C for 2 minutes and are gently inclined at 1 
minute interval until one can be tilted at an angle >90°C without 
spilling or flowing out of blood. 
 The stopwatch is stopped. Similarly, this is done with second tube 
simultaneously. 
 Clotting time is expressed as mean of the two readings. 
 Normal Clotting Time is 4-9 minutes. 
PROTHROMBIN TIME (PT) AND INTERNATIONAL 
NORMALISED RATIO (INR): 
 Measures the time taken for fibrin formation through extrinsic and 
common pathways of coagulation. It measures the activity of factor VII, 
factor V, factor X, factor II and fibrinogen. 
Principle: 
 Prothrombin Time is usually done with Activated Partial 
Thromboplastin Time. Prothrombin Time is discovered by Dr. Armand 
Quick and colleagues in 1935. Dr. Paul Owren named as “p and p” or 
prothrombin and proconvertin method. 
 Collection of blood for the PT test by using siliconized glass or 
polypropylene syringe with large bore needle (20Gauge or 21Gauge). 
Venous blood is collected from the syringe, needle is removed and the 
blood is passed gently in the anticoagulant containing tube. For collection 
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of blood, glass syringes should be avoided and also blood should not be 
drawn from the indwelling catheter. 
 Anticoagulant used is 3.8% sodium citrate solution. Blood to 
anticoagulant solution ratio is 9:1. Purpose of using sodium citrate is that 
it binds with calcium. 
 Reagent used for testing the prothrombin time is Thromborel S. It 
is prepared from human placenta. Composition of this reagent is 
lyophilized human placental thromboplastin (≤60g/L), calcium chloride 
(approximately 1.5g/L). Unopened reagent should be stored at 2 to 80 C.   
 Blood is centrifuged to separate the plasma for 15-20 minutes at 
3000 revolutions per minute. Plasma is analysed by an automated 
instrument and the prothrombin time is measured. Plasma should be 
tested within 24 hours of collection.  
INR: 
 It was invented in early 1980’s by Tom Kirkwood at UK National 
Institute for Biological Standards and Control. It is used to standardize 
prothrombin time.   
   Patient PT 
INR    =  
   Mean PT 
  
 Patient PT is measured and the mean PT is obtained by 
calculating the geometric mean PT of 20 healthy persons including both 
male and female tested at same laboratory. 
ISI
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 ISI (International Sensitivity Index) of a particular tissue 
thromboplastin is derived by comparing it with a reference 
thromboplastin of known ISI. It is a sensitivity index specific to each 
reagent instrument combination.  
 The reference range for PT is 12-13 seconds. For INR the 
reference range is 0.8-1.2 seconds. 
ACTIVATED PATIAL THROMBOPLASTIN TIME: 
 The older name is kaolin Cephalin Time. It was first described in 
1953 by researchers at The University of North Carolina at Chapel Hill. 
This test measures the clotting time of plasma after activation of contact 
factors and addition of phospholipid and calcium chloride. Phospholipid 
used for activation of the plasma and the calcium is used to reverse the 
effect of sodium citrate which is the anticoagulant used. This test 
measures the efficacy of intrinsic and common pathway of coagulation. 
Normal APTT time requires the following coagulation factors, factor I, II, 
V, VIII, IX, X, XI and XII. 
Reagents Used for Testing APTT: 
Activated Cephaloplastin reagent:  
 It is extracted from dehydrated rabbit brain in ellagic acid. Store 
the closed container at +2 to +8 °C. It activates the factors of intrinsic 
coagulation system in measuring APTT. 
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Calcium Chloride: 
 It is a ready to use solution standardized at 0.025 mol/l 
concentration. On activation of contact factors by the activator in the 
APTT reagents, Factor XIIa is produced that cleaves factor XI to XIa. 
The partial thromboplastin time is then measured by adding appropriate 
amount of Calcium Chloride.  
 Samples are collected and plasma is prepared as for that of 
prothrombin time test. By automated analyser APTT is measured. The 
normal range is 28-32 seconds. 
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DESIGN, METHODOLOGY AND TECHNIQUES 
 
1. SOURCE OFDATA: 
 Pregnant women with pregnancy induced hypertension admitted 
in The Department of Obstetrics, Coimbatore Medical College Hospital, 
Coimbatore.Normal pregnant women, attending outpatient clinic in the 
Department of Obstetrics, Coimbatore Medical College Hospital, 
Coimbatore. 
2.STUDY PLACE: 
The Department of Pathology, Coimbatore Medical College 
Hospital, Coimbatore. 
3.STUDY PERIOD: 
 Prospective study from July 2013 toJuly2014. 
4. STUDY DESIGN: 
Case control study 
5. SAMPLE SIZE:   
120 
6. INCLUSION CRITERIA: 
Normotensive pregnant women consist of 60 persons. 
Pregnancy induced hypertension patients are divided into two groups. 
GROUP I: Non severe pregnancy induced hypertension-30 cases. 
GROUP II: Severe pregnancy induced hypertension-30 cases.  
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7. EXCLUSION CRITERIA: 
 Previous history of hypertension. 
 Previous history of diabetes mellitus. 
 Previous history of renal disease. 
 Previous history of coagulation abnormalities 
METHODOLOGY: 
 Study conducted at Coimbatore Medical College, Coimbatore 
from July 2013 to July2014. Study group consists of 120 pregnant 
women from the department of obstetrics, Coimbatore Medical College. 
In which 60 pregnant women were selected for control group with normal 
blood pressure .The remaining 60 pregnant women with systolic blood 
pressure of 140 mmHg and above and diastolic blood pressure of 
90mmHg and above. Both the groups were in the same age group that is 
between 20 to 30 years and the period of pregnancy which is between 36 
to 39 weeks. Both study groups were matched.  
 Those with blood pressure 140/90mmHg and above are divided in 
to two groups.The nonsevere PIH group consists of 30pregnant women 
with blood pressure between 140/90mmHg and 160/110mmHg. The 
severe PIH group consists of 30 pregnant women with systolic blood 
pressure above 160mmHg and diastolic blood pressure above 110mmHg 
with symptoms like vomiting, headache,Visual Disturbances, Upper 
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abdominal Pain, Oliguria, Convulsion, Low platelet Count, Elevated 
serum enzymes and creatinine. 
 Detailed medical and obstetric history taken from the study group 
and procedure explained. After getting consent, the following tests were 
done. 
1. Bleeding time –By DUKE’S method. 
2. Clotting time –Wright’ capillary tube method. 
3. Platelet count-By Automated Haematology Analyser SYSMEX 
XP-100. 
4. Prothrombin Time and APTT- By using Automated Analyser 
SYSMEX CA-50. 
Platelet Count Estimation Method: 
1. Collect venous blood sample with EDTA anticoagulant. 
2. Make sure that Ready is displayed on the instrument status 
indicator at the top of the display area and analysis mode is set to 
whole blood mode. 
3. Mix the sample by inverting the sample tube. 
4. Remove the cap while taking care not allow blood scatter. 
5. Set the tube to the sample probe, and in that condition, press the 
start switch. 
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6. The analysis starts, the status display indicates Aspirating. When 
sample aspiration is completed, status display changes to Running. 
When Running is displayed the sample can be removed safely. 
7. The analysis results are displayed 60 seconds after starting the 
analysis.  
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Figure: Vaccutinor used for the collection of blood for the estimation of 
platelet count. 
 
 
 Vaccutinor contains anticoagulant EDTA.Blood is collected and 
platelet count estimation done by autoanalyzer.  
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Figure: Analyser used for estimation of platelet count 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By this analyser platelet count is estimated by automated method. 
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PROTHROMBIN TIME:  
1. 2ml Venous blood is collected with anticoagulant trisodium citrate 
and centrifuged to get plasma. By using automated blood 
coagulation analyser sysmex CA 50 prothrombin time is measured 
from the plasma by the following steps. 
2. Add 50 µl of blood sample into the cuvette and press start button.  
3. Wait for beep after one minute and then add 100 µl of 
prothrombin time reagent and close the lid. Note the reading from 
the analyser. 
ACTIVATED PARTIAL THROMBOPLASTIN TIME  
  2ml Venous blood is collected with anticoagulant trisodium 
citrate and centrifuged to get plasma. By using automated blood 
coagulation analyser sysmex CA 50 activated partial thromboplastin 
time is calculated from the plasma by the following steps. 
1. Add 50 µl of blood sample into the cuvette and press start 
button. 
2. Wait for the beep after one minute add 50 µl of activated partial 
thromboplastin time reagent and close the lid. 
3. Wait for the beep after 3 minutes and then add 50 µl of calcium 
chloride forcibly into the cuvette and close the lid. 
4. Note the reading from the analyser. 
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Figure: Vaccutinor used for collection of blood for PT and APTT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 It contains 3.8% sodium citrate solution as an anticoagulant. Used 
for estimation of prothrombin time and activated partial thromboplastin 
time.  
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Figure: Reagents used for estimation of prothrombin time and 
activated partial thromboplastin time. 
 
 Calcium chloride and Actin are used for estimation of activated 
partial thromboplastin time.  
 Thromborel S is used for estimation of prothrombin time.  
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Figure: Analyser used for estimation of prothromin time and activated 
partial thromboplastin time. 
 
 By this analyser PT, APTT and fibrinogen levels are estimated by 
automated method.  
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OBSERVATION AND RESULTS 
 
 Statistical methods used for analysis of Coagulation Parameters 
include SPSS 18 software, Anova, Scheffe, Post Hoc test and one way 
Bleeding time (in seconds): 
Table 1: Distribution of patients according to Bleeding Time: 
 
BLEEDING 
TIME 
(seconds) 
CLINICAL DIAGNOSIS 
TOTAL Normal 
pregnancy 
% 
PIH 
Non 
severe 
% 
PIH 
severe 
% 
110-150 30 50 02 7 00 0 32 
150-190 27 45 20 67 00 0 47 
190-230 03 5 08 27 15 50 26 
230-260 00 0 00 0 15 50 15 
Total 60 100 30 100 30 100 120 
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 Normal Pregnancy- among 60 normal pregnant women, 30 
women (50%) showed BT between 110-150 seconds.27 women (45%) 
revealed BT between 150-190 seconds and 3(5%) revealed BT between 
190-230 seconds. 
 Nonsevere PIH- among 30 cases, 2 (7%) cases revealed BT 
between 110-150 seconds, 20(67%) cases showed BT between 150-190 
seconds and 8(27%) cases showed BT between 190-230 seconds. 
 Severe PIH-Among 30 cases, 15(50%) cases revealed BT 
between 110-150 seconds, 15(50%) cases showed BT between 150-190 
seconds. 
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Table 2: Mean Bleeding Time for Normal Pregnancy, Non Severe 
PIH and Severe PIH Patients. 
 
Bleeding time (in seconds) 
 Number Mean Std.Deviation Std.Error 
Normal 
Pregnancy 
60 153.5333 23.95014 3.09195 
Non 
Severe PIH 
30 178.5333 23.83815 4.35223 
Severe PIH 30 227.4667 21.21114 3.87261 
Total 120 178.2667 38.09491 3.47757 
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Chart 1: The mean Bleeding Time of Normal Pregnancy, Non severe 
PIH and severe PIH. 
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Table 3: Analysis of variance of Bleeding Time among group Normal 
Pregnancy, Non severe PIH and Severe PIH 
Anova 
 
 Sum of squares Df Mean square F Sig 
Between 
Groups 
109325.6 2 54662.800 100.924 0.000 
Within 
Groups 
63369.867 117 541.623   
Total 172695.5 119    
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Table 4: Multiple Comparisons of Bleeding time among group 
Normal Pregnancy, Non severe PIH and Severe PIH 
Dependant variable: Bleeding Time (Seconds) 
Scheffe 
(I)Blood  
Pressure 
(J)Blood  
Pressure 
Mean  
Difference (I-J) 
Std. 
Error 
Sig. 
Normal 
Pregnancy 
Non Severe PIH 
Severe PIH 
-25.00000* 
-73.93333* 
5.20395 
5.20395 
0.000 
0.000 
Non Severe  
PIH 
Normal Pregnancy 
Severe PIH 
25.00000* 
-48.93333* 
5.20395 
6.00901 
0.000 
0.000 
Severe PIH 
Normal Pregnancy 
Non Severe PIH 
73.93333* 
48.93333* 
5.20395 
6.00901 
0.000 
0.000 
*. The mean difference is significant at the 0.05 level. 
 From the above tables the mean bleeding time of normal 
pregnancy, for the non-severe PIH and for the severe PIH were 153.53 
seconds, 178.53 seconds and 227.46 seconds respectively. 
 The F value 100.924 for the mean difference in the Bleeding time 
between the normal pregnancy, nonsevere PIH and severe PIH patients 
were significant.(p value <0.001). Further post hoc analysis revealthat the 
patients with severe PIH showed prolonged bleeding time compared to 
non-severe PIH and normotensive pregnant women. 
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CLOTTING TIME  
Table 5: Distribution of patients according to Clotting Time 
 
 The above table showed the normal pregnancy constitutes 60 
women,in which 20 had CT between 210-260seconds,14 had CT between 
CLOTTING 
TIME 
(seconds) 
CLINICAL DIAGNOSIS 
TOTAL Normal 
pregnancy 
% 
PIH 
Non 
severe 
% 
PIH 
severe 
% 
210-260 20 33 12 40 12 40 44 
260-310 14 23 08 27 10 33 32 
310-360 12 20 06 20 03 10 21 
360-410 08 14 04 13 03 10 15 
410-460 03 5 00 0 02 7 05 
460-510 03 5 00 0 00 0 03 
Total 60 100 30 100 30 100 120 
 84 
260-310 seconds, 12 showed CT between 310-360 seconds,8 revealed CT 
between 360-410 seconds,3 showed CT between 410- 460 and 3 had CT 
between 460-510. 
 Non severe PIH-The above table showed 30 cases in which 12 
had CT between 210-260seconds,8 had CT between 260-310 seconds, 6 
showed CT between 310-360 seconds and4 revealed CT between 360-
410 seconds. 
 Severe PIH-The above table showed 30 cases in which 12 had CT 
between 210-260seconds,10 had CT between 260-310 seconds, 3 showed 
CT between 310-360 seconds,3 revealed CT between 360-410 seconds 
and 2had CT between 410-460 seconds.  
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Table 6: Mean Clottingtime (in seconds) for Normal Pregnancy, Non 
Severe PIH and Severe PIH Patients. 
 Number  Mean Std.Deviation Std.Error 
Normal 
Pregnancy 
60 310.5667 70.73857 9.13231 
Non Severe 
PIH 
30 290.2000 55.07950 10.05610 
Severe PIH 30 292.4000 61.90850 11.30289 
Total 120 300.9333 65.18026 5.95012 
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Chart 2: The mean Clotting Time of Normal Pregnancy, Non 
severe PIH and severe PIH. 
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Table 7: Analysis of variance of Clotting Time among group Normal 
Pregnancy, Non severe PIH and Severe PIH 
Anova 
 
 Sum of squares Df Mean square F Sig 
Between 
Groups 
11208.733 2 5604.367 1.326 0.269 
Within 
Groups 
494358.7 117 4225.288   
Total 505567.5     
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Table 8: Multiple Comparisons of Clotting time among group 
Normal Pregnancy, Non severe PIH and Severe PIH 
Dependant variable: ClottingTime (Seconds) 
Scheffe 
(I)Blood  
Pressure 
(J)Blood Pressure 
Mean 
Difference        
(I-J) 
Std. 
Error 
Sig. 
Normal  
Pregnancy 
Non Severe PIH 
Severe PIH 
20.36667 
18.16667 
14.53494 
14.53494 
0.378 
0.460 
Non Severe  
PIH 
Normal Pregnancy 
Severe PIH 
-20.36667 
-2.20000 
14.53494 
16.78350 
0.378 
0.991 
Severe PIH 
Normal Pregnancy 
Non Severe PIH 
-18.16667 
2.20000 
14.53494 
16.78350 
0.460 
0.991 
 
 From the above tables the mean clotting time of nomal pregnancy, 
nonsevere PIH and severe PIH patients were 310.56 seconds,290 seconds 
and 292 seconds respectively. 
 In the above tables the F value for the mean difference in the 
clotting time between the normal pregnancy,nonsevere PIH and severe 
PIH were not significant.(P value 0.269) 
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PLATELET COUNT: 
Table 9: Distribution of patients according to Platelet Count 
 
 
 
 
  
PLATELET 
COUNT 
(lacs/mm3) 
CLINICAL DIAGNOSIS 
TOTAL Norma 
pregnancy 
% 
PIH 
Non 
severe 
% 
PIH 
severe 
% 
0.6-1.6 02 3 02 7 18 60 22 
1.6-2.6 14 23 24 80 12 40 50 
2.6-3.6 34 57 04 13 00 0 38 
3.6-4.3 10 17 00 0 00 0 10 
Total 60 100 30 100 30 100 120 
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Table10 : Mean Platelet Count (Lakhs) for Normal Pregnancy, 
Non Severe PIH and Severe PIH Patients. 
 Number Mean Std. Deviation Std.Error 
Normal 
Pregnancy 
60 2.8950 0.76469 0.10259 
Non Severe 
PIH 
30 2.1707 0.55797 0.10187 
Severe PIH 30 1.5880 0.57666 0.10528 
Total 120 2.3872 0.87914 0.08025 
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Chart 3: The mean Platelet Count of Normal Pregnancy, Non severe 
PIH and severe PIH. 
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Table 11: Analysis of variance of Platelet Count among group 
Normal Pregnancy, Non severe PIH and Severe PIH 
Anova 
 
Sum of 
squares 
Df 
Mean 
square 
F Sig 
Between Groups 36.040 2 18.020 37.694 0.000 
Within Groups 55.933 117 0.478   
Total 91.973 119    
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Table 12: Multiple Comparisons of Platelet Count among group 
Normal Pregnancy, Non severe PIH and Severe PIH 
Dependant variable:  Platelet Count (Lakhs) 
Scheffe 
(I)Blood 
Pressure 
(J)Blood  
Pressure 
Mean  
Difference(I-J) 
Std. 
Error 
Sig. 
Normal  
Pregnancy 
Non Severe PIH 
Severe PIH 
0.72433* 
1.30700* 
0.15461 
0.15461 
0.000 
0.000 
Non Severe  
PIH 
Normal Pregnancy 
Severe PIH 
-0.72433* 
0.58267* 
0.15461 
0.17852 
0.000 
0.006 
Severe  
PIH 
Normal Pregnancy 
Non Severe PIH 
-1.30700* 
-0.58267* 
0.15461 
0.17852 
0.000 
0.006 
*. The mean difference is significant at the 0.05 level 
 From the above table the mean platelet count of normal 
pregnancy, nonsevere PIH and severe PIH patients were 2.89 
lacs/cumm,2.17lacs/cumm and 1.58 lacs/cumm were respectively. 
 The F value for the mean difference in the platelet count between 
the normal pregnancy,nonsevere PIH and severe PIH patients were 
significant.(P value <.000). 
 Further the Post Hoc Test analysis reveals that the patients with 
severe PIH show decrease in platelet count compared to nonsevere PIH 
and normal pregnancy groups.  
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PROTHROMBIN TIME: 
Table 13: Distribution of patients according to Prothrombin Time: 
PROTHROMBIN 
TIME (seconds) 
CLINICAL DIAGNOSIS 
TOTAL Normal 
pregnancy 
% 
PIH 
Non 
severe 
% 
PIH 
severe 
% 
8-10 10 17 15 50 03 10 28 
10-12 36 60 12 40 06 20 54 
12-14 14 23 03 10 15 50 32 
14-20 00 0 00 0 06 20 06 
Total 60 100 30 100 30 100 120 
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Table14 : Mean Prothrombin time (in seconds) for Normal 
Pregnancy, Non Severe PIH and Severe PIH Patients. 
 
 Number Mean Std.Deviation Std.Error 
Normal 
Pregnancy 
60 11.1050 1.36797 0.17660 
Non Severe 
PIH 
30 10.1933 1.53801 0.28080 
Severe PIH 30 13.0667 2.74846 0.50180 
Total 120 11.3675 2.11076 0.19269 
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Chart 4: The mean Prothrombin Time of Normal Pregnancy, Non 
severe PIH and severe PIH. 
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Table 15: Analysis of variance of Prothrombin Time among group 
Normal Pregnancy, Non severe PIH and Severe PIH 
Anova 
 
Sum of 
squares 
Df 
Mean 
square 
F Sig 
Between 
Groups 
132.109 2 66.055 19.414 0.000 
Within 
Groups 
398.074 117 3.402   
Total 530.183 119    
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Table 16: Multiple Comparisons of Prothrombin Time among group 
Normal Pregnancy, Non severe PIH and Severe PIH 
Dependant variable: ProthrombinTime (Seconds) 
Scheffe 
(I)Blood 
Pressure 
(J)Blood 
Pressure 
Mean 
Difference        
(I-J) 
Std. 
Error 
Sig. 
Normal 
Pregnancy 
Non Severe PIH 
Severe PIH 
0.91167 
-1.96167* 
0.41245 
0.41245 
0.091 
0.000 
Non Severe PIH 
Normal Pregnancy 
Severe PIH 
-0.91167 
-2.87333* 
0.41245 
0.47626 
0.091 
0.000 
Severe PIH 
Normal Pregnancy 
Non Severe PIH 
1.96167 
2.87333* 
0.41245 
0.47626 
0.000 
0.000 
*. The mean difference is significant at the 0.05 level 
 From the above table the mean prothrombin time of normal 
pregnancy,nonsevere PIH and severe PIH were 11.0 seconds, 10.19 
seconds and 13.066 respectively. 
 The F value for the mean difference in the prothrombin time 
between the normal pregnancy,nonsevere PIH and severe PIH patients 
were significant.(P value <0.000). 
 Further Post Hoc Test analysis show that patients with severePIH 
show increase in prothrombin time. 
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Activated Partial Thromboplatin Time: 
 
Table 17: Distribution of patients according to APTT: 
 
APTT 
(seconds) 
CLINICAL DIAGNOSIS 
TOTAL Normal 
pregnancy 
% 
PIH 
Non 
severe 
% 
PIH 
severe 
% 
22-25 11 18 04 13 03 10 18 
25-28 10 17 06 20 05 17 21 
28-31 21 35 08 27 06 20 35 
31-36 18 30 12 40 10 33 40 
36-40 00 0 00 0 06 20 06 
Total 60 100 30 100 30 100 120 
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Table 18 : Mean APTT (in seconds) for Normal Pregnancy, Non 
Severe PIH and Severe PIH Patients. 
 
 Number Mean Std.Deviation Std.Error 
Normal Pregnancy 60 29.3633 3.78999 0.48929 
Non Severe PIH 30 29.5000 3.78080 0.69028 
Severe PIH 30 32.2867 5.44836 0.99473 
Total 120 30.1283 4.40548 0.40216 
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Chart 5: The mean APTT of Normal Pregnancy, Non severe PIH and 
severe PIH. 
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Table 19: Analysis of variance of APTT among group Normal 
Pregnancy, Non severe PIH and Severe PIH 
Anova 
 
Sum of 
squares 
Df 
Mean 
square 
F Sig 
Between Groups 186.710 2 93.355 5.145 0.007 
Within Groups 2122.874 117 18.144   
Total 2309.584 119    
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Table 20: Multiple Comparisons of APTT among group Normal 
Pregnancy, Non severe PIH and Severe PIH 
Dependant variable: APTT (Seconds) 
Scheffe 
(I)Blood 
Pressure 
(J)Blood Pressure 
Mean 
Difference        
(I-J) 
Std. 
Error 
Sig. 
Normal 
Pregnancy 
Non Severe PIH 
Severe PIH 
-0.13667 
-2.92333* 
0.95248 
0.95248 
0.990 
0.011 
Non Severe PIH 
Normal Pregnancy 
Severe PIH 
0.13667 
-2.78667* 
0.95248 
1.09982 
0.990 
0.044 
Severe PIH 
Normal Pregnancy 
Non Severe PIH 
2.92333* 
2.78667* 
0.95248 
1.09982 
0.011 
0.044 
*. The mean difference is significant at the 0.05 level 
 From the above table the mean APTT of normal 
pregnancy,nonsevere PIH and severe PIH patients were 29.36 
seconds,29.5seconds and 32.28 seconds were respectively. 
 The F value for the mean difference between normal pregnancy, 
nonsevere PIH and severe PIH patients were significant. (P value 0.007). 
 Further Post Hoc Test analysis reveals patients with severe PIH 
show increased in APTT value compared to normal pregnancy and 
nonsevere PIH 
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DISCUSSION 
 
Bleeding Time: 
 Present study showed the mean bleeding time for normal 
pregnancy, non-severe PIH and severe PIH were 153 seconds, 178 
seconds and 227 seconds respectively. P-value <0.000 is significant. 
 Priyanka Chauchan[100] et al 2014 study showed bleeding time for 
normal pregnancy, nonsevere PIH and severe PIH were 180 seconds, 294 
seconds and 324 seconds respectively, with significant p-value (<0.001). 
So this study correlated well with present study. 
Clotting Time: 
 Present study showed the mean clotting time for normal 
pregnancy was 310 seconds, clotting time for the non-severe PIH was 290 
seconds and the severe PIH was 292 seconds, the P-value 0.269 is not 
significant. 
 The mean clotting time compared with Priyanka Chauchan et al 
2014 study, which showed the mean clotting time for normal pregnancy 
was 358 seconds, for the non-severe PIH was 368 seconds and for the 
severe PIH was 378 seconds. P-value more than 0.05 was not significant.  
 There will be interobserver variations in doing clotting time 
estimation. 
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Platelet Count: 
 In the present study the mean platelet count of normal pregnancy, 
non-severe PIH and severe PIH patients were 2.89 lakhs/cubic mm, 2.17 
lakhs/cubic mm and 1.58 lakhs/cubic mm respectively, with significant P-
value 0.000. These values correlated with following studies: 
 Shete Anjali [101] et al 2013 study showed the mean platelet count 
in normal pregnancy was 3.41 lakhs/cubic mm and in severe PIH 1.27 
lakhs/cubic mm and the significant P-value <0.05. 
 Bhia Namavar Jahrom[47] et al 2009 revealed the mean platelet 
count of normal pregnancy and severe PIH were 2.33 lakhs/cubis mm and 
1.5 lakhs/ cubic mm with significant P-value <0.001. 
 Sameer[102] et al April 2014 indicated the mean platelet count in 
normal pregnancy was 2.39 lakhs/cubic mm and severe PIH was 1.6 
lakhs/cubic mm with significant P-value <0.001. 
 Priyanka Chauchan[100] et al 2013 study exhibited the mean ± 
standard deviation of platelet count in normal pregnancy was 2.47 ± 0.75 
lakhs/cubic mm, mean ± standard deviation of platelet count in nonsevere 
PIH was 1.62 ± 0.678 lakhs/cubic mm and mean ± standard deviation of 
platelet count in severe PIH 1.63 ± 0.742 lakhs/cubic mm. The P-value 
was significant (<0.001). 
 Elloradevi[103] et al 2012 revealed the platelet count in normal 
pregnancy, nonsevere PIH and severe PIH were 2.44 ± 0.11 lakhs/cubic 
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mm, 1.82 ± 0.19 lakhs/ cubic mm and 1.42 ± 0.23 lakhs/ cubic mm 
respectively with significant P-value <0.05. 
 S. Mohapatra[104] et al exhibited the mean platelet count in normal 
pregnancy was 2.38 ± 0.33 lakhs/cubic mm , mean platelet count in 
nonsevere PIH was 1.82 ± 0.45 lakhs/cubic mm and mean platelet count 
in severe PIH 1.21 ± 0.49 lakhs/cubic mm with P-value of <0.1. 
 Studies above mentioned were correlated well with present study 
for the mean platelet count and the P-value. 
Prothrombin time: 
      In present study the mean prothrombin time for normal pregnancy, 
non-severe PIH and severe PIH patients were 11.05 seconds, 10.19 
seconds and 13.06 seconds respectively, with significant P-value <0.000. 
 Wale Mohamed Aref[105] et al 2012 study showed the mean 
prothrombin time for normal pregnancy and severe PIH patients were 
13.24 ± 0.86 seconds and  13.41 ± 0.68  seconds respectively, with P-
value more than 0.05  
 Tashin Mushtaque [106] et al 2013 study revealed the mean 
prothrombin time for normal pregnancy, Non severe PIH and severe PIH 
patients were 10.9 seconds, 10.1 seconds and  9.8 seconds respectively, 
with P-value less than 0.0001 was statistically significant 
 The above two studies statistically correlated with present study. 
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APTT: 
 In present study the mean APTT for normal pregnancy, non-
severe PIH and severe PIH patients were 29.3 seconds, 29.5 seconds and 
32.2 seconds respectively, with significant P-value <0.007. 
 Tashin Mushtaque [106] et al 2013 study revealed the mean APTT 
for normal pregnancy, Non severe PIH and severe PIH patients were 
26.68 seconds, seconds 26.71 and 26.25 seconds respectively, with P-
value less than 0.005 was statistically significant. 
The present study correlated well with the above study. 
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SUMMARY 
 
 Study conducted at Coimbatore Medical College, Coimbatore 
during the year 2013-2014. The thesis study titled as “COAGULATION 
PROFILE STUDY IN PREGNANCY INDUCED HYPERTENSION”. It 
is a case control prospective study in which 60 control groups and 60 
study groups. Control group includes normotensive pregnant woman and 
study group consists of two groups, one is Non Severe PIH and the other 
is Severe PIH. For all the groups coagulation parameters which includes 
BT, CT, Platelet Count, PT and APTT were done. Statistical analysis 
done which were compared with various available previous studies. 
 
 Present study showed the mean bleeding time for normal 
pregnancy, nonsevere PIH and severe PIH were 153 seconds, 178 
seconds and 227 seconds respectively. P-value less than 0.000 is 
significant. 
 Present study showed the mean clotting time for normal pregnancy 
was 310 seconds, clotting time for the nonsevere PIH was 290 
seconds and the severe PIH was 292 seconds, the P-value 0.269 is 
not significant. 
 In the present study the mean platelet count of normal pregnancy, 
nonsevere PIH and severe PIH patients were 2.89 lakhs/cubic mm, 
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2.17 lakhs/cubic mm and 1.58 lakhs/cubic mm respectively, with 
significant P-value less than 0.000. 
 In present study the mean prothrombin time for normal pregnancy, 
non-severe PIH and severe PIH patients were 11.05 seconds, 10.19 
seconds and 13.06 seconds respectively, with significant P-value 
less than 0.000. 
 In present study the mean APTT for normal pregnancy, nonsevere 
PIH and severe PIH patients were 29.3 seconds, 29.5 seconds and 
32.2 seconds respectively, with significant P-value less than 0.007. 
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CONCLUSION 
 
 Present study revealed changes in the coagulation parameters in 
women with severe pregnancy induced hypertension which was 
compared to normotensive pregnant women and in women with 
non-severe pregnancy induced hypertension. 
 Platelet count showed inverse relationship with severity of 
pregnancy induced hypertension.  
 Bleeding time, Prothrombin time and Activated Partial 
Thromboplastin time showed prolonged values with severe 
pregnancy induced hypertension. 
 With increasing severity of blood pressure in pregnant women 
changes noted in the coagulation parameters.  
 Current maternal mortality in India is 212 per one lakh live births 
and in Tamil Nadu it is 178 per one lakh live births. 
 Coagulation abnormalities include HELLP syndrome and 
disseminated intra vascular coagulation contribute the causes for 
maternal deaths in pregnancy induced hypertension. 
 Present study can be helpful in identifying the coagulation 
abnormalities in relation to pregnancy induced hypertension in 
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earlier stage and can be helpful for the management of 
complications in relation to pregnancy induced hypertension. 
 Maternal and fetal mortality and morbidity can be reduced with the 
help of this study. 
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ANNEXURE-1 
DEPARTMENT OF PATHOLOGY,  
COIMBATOREMEDICAL COLLEGE 
HOSPITAL,COIMBATORE 
PROFORMA 
COAGULATION PROFILE STUDY IN PREGNANCY INDUCED 
HYPERTENSION 
NAME                :                                                              OP/ID NO  : 
AGE                   :                                                       DEPARTMENT : 
SEX                   : 
OCCUPATION : 
ADDRESS         : 
1) Clinical Details 
a) Complaints/ period of amenorrhoea 
b) Past History 
c) Past Obstetrics History 
d) Menstrual History 
e) Family History 
f) General Examination BP 
g) Systematic Examination 
CVS 
RS 
CNS 
PA 
2) Investigations 
a) Routine HB, Urine 
b) USG Examination 
3) Clinical Diagnosis 
4) Coagulation 
Parameter Analysis 
Bleeding Time 
Clotting Time 
Platelet Count 
Prothrombin Time and 
Activated Partial Thromboplastin Time 
 
 
 
 
  
 KEY TO MASTER CHART 
 
APTT - Activated Partial Thromboplastin Time 
P             -  Primi 
G2P1      -  Gravida 2 Para 1 
NP          -  Normal Pregnancy 
NSPIH    -  Non Severe Pregnancy Induced Hypertension 
SPIH       -  Severe Pregnancy Induced Hypertension 
  
ANNEXURE-III 
CONSENT FORM 
 
Dr.S.VIJAYALAKSHMI, postgraduate student in the Department 
of Pathology, Coimbatore Medical College Hospital is conducting a study 
on “COAGULATION PROFILE STUDY IN PREGNANCY 
INDUCED HYPERTENSION”.The study and test procedures were 
explained to me clearly. I hereby give my consent to participate in this 
study and to give blood sample. The data obtained herein may be used for 
research and publication.  
Name:  
Place:  
Signature:  
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1 Anu 23 47537 P 37 ‐ ‐ ‐ ‐ ‐ ‐ 110/70 ‐ NP 156 1.58 278 8.7 22.2
2 Manju 23 47573 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 142/96 ‐ NSPIH 194 1.64 212 8.2 22.2
3 Banu 26 42943 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 116/72 ‐ NP 148 4.2 336 12.2 23.2
4 Abi 25 46552 P 37 ‐ ‐ ‐ ‐ ‐ ‐ 120/70 ‐ NP 170 1.68 366 12.4 24.2
5 Divya 23 42943 G2P1 39 ‐ ‐ ‐ ‐ ‐ ‐ 118/76 ‐ NP 144 3.24 274 9.3 24.6
6 Amsa 24 46749 P 39 ‐ ‐ ‐ ‐ ‐ ‐ 148/94 Trace NSPIH 178 1.72 392 8.4 23.2
7 Priya 28 43071 P 39 ‐ ‐ ‐ ‐ ‐ ‐ 116/74 ‐ NP 180 2.68 466 11.2 30.6
8 Revathi 26 46576 G2P1 38 ‐ ‐ ‐ ‐ ‐ ‐ 120/80 ‐ NP 136 3.12 334 11.2 30.8
9 Tamil selvi 28 47318 P 37 ‐ ‐ ‐ ‐ ‐ ‐ 150/92 1+ NSPIH 182 1.86 216 8.6 24.2
10 Radhika 25 47417 G2P1 37 ‐ ‐ ‐ ‐ ‐ ‐ 116/78 ‐ NP 176 2.42 376 11.6 28.6
11 Sangeetha 23 47385 G2P1 37 ‐ ‐ ‐ ‐ ‐ ‐ 110/80 ‐ NP 142 3.94 222 11.8 30.8
12 Manimegalai 26 47676 P 39 ‐ ‐ ‐ ‐ ‐ ‐ 156/100 ‐ NSPIH 112 2.42 246 9.2 22.4
13 Charulatha 29 47663 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 118/74 ‐ NP 144 2.64 248 10.2 30.6
14 Sujitha 24 47727 P 37 ‐ ‐ ‐ ‐ ‐ ‐ 110/80 ‐ NP 220 2.76 252 11.6 30.4
15 Chellamal 25 47642 P 39 ‐ ‐ ‐ ‐ ‐ ‐ 148/98 1+ NSPIH 154 1.74 236 9.4 25.2
16 Christy 27 48615 G2P1 38 ‐ ‐ ‐ ‐ ‐ ‐ 120/70 ‐ NP 148 2.86 256 11.8 30.2
17 Jancy 27 48557 G2P1 38 ‐ ‐ ‐ ‐ ‐ ‐ 110/70 ‐ NP 136 4.22 246 8.5 29.2
18 Sumathy 26 47631 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 162/110 Trace SPIH 258 1.46 268 10.2 30.2
19 Lakshmi 25 8968 G2P1 38 ‐ ‐ ‐ ‐ ‐ ‐ 112/72 ‐ NP 136 3.62 226 9.8 28.2
20 Chithra 24 38523 P 37 ‐ ‐ ‐ ‐ ‐ ‐ 150/92 ‐ NSPIH 198 0.62 226 9.6 26.4
21 Fathima 23 36753 P 39 ‐ ‐ ‐ ‐ ‐ ‐ 180/112 Trace SPIH 246 1.52 272 9.2 30.4
22 Anu priya 28 47734 P 39 ⁺ ⁺ ‐ ‐ ‐ ‐ 168/116 1+ SPIH 244 1.72 292 9.6 30.6
23 Sindhuja 28 48573 G2P1 39 ‐ ‐ ‐ ‐ ‐ ‐ 110/76 ‐ NP 134 2.92 236 10.2 33.6
24 Aysha 29 6992 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 120/80 ‐ NP 188 1.64 352 10.4 30.8
25 Sanjana 23 8659 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 118/76 ‐ NP 132 2.12 468 11.2 35.8
26 Suba lakshmi 25 49655 P 37 ‐ ‐ ‐ ‐ ‐ ‐ 122/78 ‐ NP 178 2.82 228 10.8 30.2
27 Banumathi 27 6876 G2P1 37 ‐ ‐ ‐ ‐ ‐ ‐ 158/94 ‐ NSPIH 162 2.46 216 11.8 26.2
28 Sri devi 27 7385 P 37 ‐ ‐ ‐ ‐ ‐ ‐ 118/70 ‐ NP 144 3.42 332 8.2 27.8
29 Kiruba 27 58765 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 120/80 ‐ NP 156 3.22 348 10.6 26.2
30 Lavanya 29 6749 P 38 ⁺ ⁺ ‐ ‐ ‐ ‐ 170/110 Trace SPIH 196 2.52 212 8.4 27.4
31 Subashini 25 8613 P 39 ‐ ⁺ ‐ ‐ ‐ ‐ 180/116 1+ SPIH 210 1.32 214 12.4 28.2
MASTER CHART
32 Vasuki 24 52314 G2P1 39 ‐ ‐ ‐ ‐ ‐ ‐ 120/70 ‐ NP 154 3.38 398 10.4 24.6
33 Hari priya 23 55512 P 37 ⁺ ⁺ ⁺ ‐ ‐ ‐ 176/118 1+ SPIH 232 1.36 298 11.4 26.6
34 Preethi 25 42671 P 37 ‐ ‐ ‐ ‐ ‐ ‐ 118/74 ‐ NP 168 2.96 344 10.2 26.8
35 Raja rajeshwari 24 76428 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 112/76 ‐ NP 148 3.84 386 13.4 27.2
36 Diana 25 56732 P 39 ‐ ‐ ‐ ‐ ‐ ‐ 148/98 ‐ NSPIH 186 2.58 384 9.2 27.2
37 Abinaya 28 9543 G2P1 39 ‐ ‐ ‐ ‐ ‐ ‐ 118/78 ‐ NP 170 3.12 342 11.4 27.8
38 Swathi priya 27 47614 G2P1 38 ‐ ‐ ‐ ‐ ‐ ‐ 110/80 ‐ NP 132 3.26 392 11.4 27.4
39 Nandhini 25 32145 P 38 ⁺ ⁺ ‐ ‐ ‐ ⁺ 178/120 Trace SPIH 238 1.24 218 10.4 29.2
40 Steffy 24 61634 G2P1 37 ‐ ‐ ‐ ‐ ‐ ‐ 116/70 ‐ NP 148 2.46 354 11.2 26.6
41 Premalatha 23 34661 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 150/100 ‐ NSPIH 222 2.48 256 8.2 26.8
42 Kalaivani 28 43217 P 39 ‐ ⁺ ‐ ⁺ ‐ ‐ 178/116 2+ SPIH 222 1.56 242 10.8 29.4
43 Viji 27 56903 P 39 ‐ ‐ ‐ ‐ ‐ ‐ 112/70 ‐ NP 114 4.28 352 11.2 25.8
44 Priya 25 65934 P 39 ⁺ ⁺ ‐ ‐ ‐ ⁺ 168/120 1+ SPIH 256 0.92 256 11.6 39.4
45 Vadiukkarasi 24 87562 P 39 ‐ ‐ ‐ ‐ ‐ ‐ 114/78 ‐ NP 164 2.8 462 11.4 30.2
46 Hemalatha 23 35791 G2P1 37 ⁺ ‐ ‐ ‐ ‐ ⁺ 180/110 1+ SPIH 228 1.48 248 11.8 39.4
47 Varshini 23 4682 P 37 ‐ ‐ ‐ ‐ ‐ ‐ 116/80 ‐ NP 210 2.84 312 13.2 25.6
48 Pravathi 23 60312 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 114/78 ‐ NP 134 1.82 356 10.2 29.2
49 Helan mary 27 8792 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 158/102 ‐ NSPIH 210 1.68 252 8.4 26.2
50 Jaya priyanka 25 37850 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 120/70 ‐ NP 174 3.42 356 12.2 24.2
51 Indhumathi 26 5129 P 39 ‐ ‐ ‐ ‐ ‐ ‐ 148/100 ‐ NSPIH 172 1.72 254 8.6 29.2
52 Daisy 29 9296 G2P1 37 ‐ ⁺ ‐ ⁺ ‐ ‐ 164/128 Trace SPIH 242 0.88 244 12.8 38.4
53 Shasmitha 25 92778 P 37 ‐ ‐ ‐ ‐ ‐ ‐ 110/80 ‐ NP 116 3.46 246 10.6 30.4
54 Aishwarya 24 7778 G2P1 39 ‐ ⁺ ‐ ‐ ⁺ ⁺ 170/118 Trace SPIH 212 0.68 246 12.6 24.6
55 Naveena 22 7541 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 112/70 ‐ NP 188 0.64 378 12.6 30.6
56 Divya 23 36597 G2P1 37 ‐ ‐ ‐ ‐ ‐ ‐ 156/100 ‐ NSPIH 178 1.58 256 8.2 29.6
57 Sowmiya 23 95855 P 39 ‐ ‐ ‐ ‐ ‐ ‐ 110/80 ‐ NP 192 1.94 278 8.6 30.8
58 Deepa 24 8056 P 39 ‐ ‐ ‐ ‐ ‐ ‐ 148/92 ‐ NSPIH 186 1.84 396 9.2 28.6
59 Latha 25 55441 P 39 ‐ ‐ ‐ ‐ ‐ ‐ 112/70 ‐ NP 186 3.28 394 12.8 30.2
60 Suganya 25 9353 G2P1 38 ⁺ ⁺ ‐ ‐ ‐ ‐ 170/110 3+ SPIH 240 0.78 256 13.6 25.6
61 Rekha 22 8453 P 38 ‐ ⁺ ‐ ‐ ‐ ⁺ 172/128 4+ SPIH 252 2.58 252 13.8 27.2
62 Pradeepa 47 36751 P 37 ‐ ‐ ‐ ‐ ‐ ‐ 120/80 ‐ NP 134 1.98 442 10.2 30.4
63 Manimegalai 25 37159 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 110/70 ‐ NP 182 4.18 298 12.6 29.6
64 Yasodha 24 42298 P 37 ⁺ ⁺ ‐ ‐ ‐ ‐ 170/116 3+ SPIH 194 2.42 454 13.4 39.4
65 Sasi priya 23 38335 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 120/70 ‐ NP 172 1.68 238 12.8 29.8
66 Kavitha 22 6871 G2P1 37 ⁺ ⁺ ‐ ‐ ‐ ‐ 174/112 4+ SPIH 198 1.48 296 13.2 27.6
67  Saranya 22 56654 G2P1 37 ‐ ‐ ‐ ‐ ‐ ‐ 116/80 ‐ NP 128 3.52 298 10.8 35.6
68 Varsha 28 36521 P 37 ‐ ⁺ ‐ ‐ ‐ ⁺ 180/120 3+ SPIH 258 2.36 258 13.8 22.2
69 Praveena 27 70803 P 37 ‐ ‐ ‐ ‐ ‐ ‐ 148/96 ‐ NSPIH 202 2.56 344 9.8 30.6
70 Narmadha 22 46132 P 39 ‐ ⁺ ‐ ‐ ⁺ ‐ 170/128 3+ SPIH 234 2.22 292 13.6 23.2
71 Niraja 25 31875 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 120/80 ‐ NP 122 2.12 292 11.8 31.2
72 Nishanthini 24 31487 P 37 ‐ ‐ ‐ ‐ ‐ ‐ 110/80 ‐ NP 158 3.82 372 11.2 31.4
73 Shanthi 24 58125 P 39 ⁺ ⁺ ‐ ‐ ‐ ⁺ 178/116 ‐ SPIH 226 2.34 248 13.2 39.4
74 Savitha 24 9512 P 38 ‐ ⁺ ‐ ‐ ⁺ ‐ 180/110 4+ SPIH 200 1.92 278 12.6 39.2
75 Revathi 22 51295 P 38 ⁺ ⁺ ‐ ‐ ‐ ‐ 190/120 3+ SPIH 248 0.86 276 12.8 39.6
76 Viveena 26 38870 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 120/80 ‐ NP 160 4.26 272 13.8 34.6
77 Nivetha 24 8592 G2P1 38 ‐ ‐ ‐ ‐ ‐ ‐ 148/94 ‐ NSPIH 182 3.24 356 9.2 30.2
78 Sindhu 26 5668 P 39 ‐ ‐ ‐ ‐ ‐ ‐ 110/70 ‐ NP 124 1.62 268 13.2 33.6
79 Brindha 27 6573 P 37 ‐ ‐ ‐ ‐ ‐ ‐ 150/100 ‐ NSPIH 200 2.48 358 10.4 30.4
80 Boomika 25 51185 G2P1 37 ‐ ‐ ‐ ‐ ‐ ‐ 110/80 ‐ NP 158 1.82 262 13.6 32.6
81 Sowmiya 23 51092 G2P1 38 ‐ ‐ ‐ ‐ ‐ ‐ 146/100 ‐ NSPIH 174 2.3 258 10.2 30.2
82 Ramya 24 52993 P 39 ‐ ‐ ‐ ‐ ‐ ‐ 150/92 ‐ NSPIH 148 2.82 312 10.6 29.2
83 Vaishnavi 24 8197 G2P1 39 ‐ ‐ ‐ ‐ ‐ ‐ 116/74 ‐ NP 136 1.74 246 13.8 33.6
84 Dharshana 22 42893 P 39 ⁺ ⁺ ‐ ‐ ‐ ‐ 162/116 2+ SPIH 206 0.98 288 12.6 34.8
85 Divya dharshini 22 51296 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 110/70 ‐ NP 134 3.72 232 12.4 34.6
86 Pavithra 22 45678 P 37 ⁺ ⁺ ‐ ‐ ‐ ⁺ 176/112 2+ SPIH 212 1.84 282 12.2 35.2
87 Mala 22 7843 G2P1 37 ‐ ‐ ‐ ‐ ‐ ‐ 156/98 ‐ NSPIH 158 2.22 388 11.2 31.2
88 Vikashini 23 32689 P 37 ‐ ‐ ‐ ‐ ‐ ‐ 150/100 ‐ NSPIH 156 1.78 248 11.4 31.4
89 Subu lakshmi 24 33109 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 110/70 ‐ NP 130 2.62 252 9.2 35.6
90 Sathya 25 32194 G2P1 37 ‐ ‐ ‐ ‐ ‐ ‐ 152/98 Trace NSPIH 176 1.8 294 9.6 31.6
91 Saroja 28 6779 G2P1 37 ‐ ‐ ‐ ‐ ‐ ‐ 120/74 ‐ NP 134 3.32 236 11.8 35.4
92 Sangeetha 26 9666 P 37 ⁺ ⁺ ‐ ‐ ‐ ⁺ 170/116 2+ SPIH 192 1.52 312 11.4 37.4
93 Priya dharshini 23 8437 G2P1 37 ‐ ‐ ‐ ‐ ‐ ‐ 116/78 ‐ NP 172 3.28 254 9.6 35.8
94 Shruthi 25 9487 P 39 ‐ ‐ ‐ ‐ ‐ ‐ 150/108 Trace NSPIH 158 1.92 314 11.8 31.8
95 Mallika 27 7895 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 112/76 ‐ NP 140 2.22 242 11.2 32.6
96 Kalai selvi 26 6554 P 39 ‐ ‐ ‐ ‐ ‐ ‐ 146/106 ‐ NSPIH 206 1.96 268 11.2 32.2
97 Chitra devi 23 35552 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 114/80 ‐ NP 130 2.86 238 10.6 32.2
98 Seetha 25 9047 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 148/104 Trace NSPIH 184 2.42 294 11.8 33.2
99 Maha lakshmi 22 8554 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 120/76 ‐ NP 158 2.72 244 10.4 34.2
100 Indhra 25 9566 G2P1 38 ‐ ‐ ‐ ‐ ‐ ‐ 140/100 1+ NSPIH 182 2.52 298 10.8 33.4
101 Janani 23 6935 P 37 ‐ ‐ ‐ ‐ ‐ ‐ 118/74 ‐ NP 140 3.24 288 10.2 32.8
102 Suba 23 39412 P 38 ⁺ ⁺ ‐ ‐ ‐ ⁺ 174/120 2+ SPIH 252 1.22 354 14.8 35.2
103 Raja kumari 23 8015 P 39 ‐ ‐ ‐ ‐ ‐ ‐ 144/102 ‐ NSPIH 170 2.56 272 10.2 34.2
104 Selvi 28 6485 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 146/100 ‐ NSPIH 160 1.96 298 11.2 34.2
105 Sujitha 24 9894 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 120/80 ‐ NP 164 2.82 296 11.8 31.2
106 Priya 25 6684 P 38 ⁺ ⁺ ‐ ‐ ‐ ‐ 176/110 2+ SPIH 216 2.48 348 14.8 37.2
107 varshini 25 5601 P 37 ‐ ‐ ‐ ‐ ‐ ‐ 116/80 ‐ NP 116 3.36 456 9.4 25.8
108 Subraja 24 9585 G2P1 37 ‐ ‐ ‐ ‐ ‐ ‐ 150/96 Trace NSPIH 156 2.64 292 13.8 33.6
109 Narmadha 23 50083 G2P1 37 ‐ ‐ ‐ ‐ ‐ ‐ 120/70 Trace NP 178 3.4 254 11.2 24.6
110 Aysha rifana 23 8098 G2P1 38 ⁺ ⁺ ‐ ‐ ⁺ ‐ 180/120 2+ SPIH 232 1.58 368 18.2 34.8
111 Sujatha 23 11557 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 110/80 ‐ NP 182 3.46 224 11.4 24.8
112 Sathya 24 8870 P 38 ⁺ ⁺ ‐ ⁺ ‐ ‐ 170/110 1+ SPIH 252 1.86 398 18.4 33.4
113 Gayathri 25 8708 P 39 ‐ ‐ ‐ ‐ ‐ ‐ 118/70 ‐ NP 156 3.28 272 10.8 24.2
114 Anisha 25 7987 P 39 ⁺ ⁺ ‐ ‐ ‐ ‐ 176/112 1+ SPIH 204 1.78 424 18.6 32.2
115 Kowsalya 25 9565 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 116/74 ‐ NP 152 2.66 252 10.4 22.2
116 Pavithra 22 50708 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 148/96 ‐ NSPIH 182 2.12 278 13.2 34.6
117 Priyanka 23 36640 G2P1 37 ‐ ‐ ‐ ‐ ‐ ‐ 118/72 ‐ NP 174 2.72 288 11.2 23.2
118 Kalyani 27 34723 G2P1 38 ‐ ‐ ‐ ‐ ‐ ‐ 144/92 ‐ NSPIH 228 3.48 292 12.4 35.6
119 Rohini 26 5486 P 38 ‐ ‐ ‐ ‐ ‐ ‐ 110/72 ‐ NP 112 2.68 424 8.4 24.8
120 Seema 23 9726 P 37 ⁺ ⁺ ‐ ⁺ ‐ ‐ 184/114 1+ SPIH 224 0.76 378 19.8 31.2
